



(11) **EP 1 117 679 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Description Paragraph(s) 86, 144, 145**

(51) Int Cl.:  
**C07K 7/06** <sup>(2006.01)</sup> **C12N 5/08** <sup>(2006.01)</sup>  
**C12N 15/11** <sup>(2006.01)</sup> **A61K 38/08** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**07.07.2010 Bulletin 2010/27**

(86) International application number:  
**PCT/IB1999/001664**

(45) Date of publication and mention  
of the grant of the patent:  
**25.11.2009 Bulletin 2009/48**

(87) International publication number:  
**WO 2000/020445 (13.04.2000 Gazette 2000/15)**

(21) Application number: **99970091.7**

(22) Date of filing: **15.09.1999**

(54) **TUMOR ANTIGENS AND CTL CLONES ISOLATED BY A NOVEL PROCEDURE**

TUMORANTIGENE UND CTL-KLONE, DIE DURCH EIN NEUES VERFAHREN ISOLIERT WURDEN  
ANTIGENES TUMORAUX ET CLONES DE LYMPHOCYTE T CYTOTOXIQUE (CTL) ISOLÉS GRACE  
A UN NOUVEAU PROCÉDÉ

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**

- **STROOBANT, Vincent**  
**1200 Brussels (BE)**
- **CORNELIS, Guy, R.**  
**1200 Brussels (BE)**
- **BOON-FALLEUR, Thierry**  
**1200 Brussels (BE)**
- **VAN DER BRUGGEN, Pierre**  
**1200 Brussels (BE)**
- **SCHULTZ, Erwin**  
**1150 Brussels (BE)**
- **WARNIER, Guy**  
**1200 Brussels (BE)**

(30) Priority: **02.10.1998 US 165863**  
**09.04.1999 US 289350**

(43) Date of publication of application:  
**25.07.2001 Bulletin 2001/30**

(73) Proprietor: **LUDWIG INSTITUTE FOR CANCER**  
**RESEARCH**  
**New York,**  
**New York 10105 (US)**

(74) Representative: **HOFFMANN EITLE**  
**Patent- und Rechtsanwälte**  
**Arabellastrasse 4**  
**81925 München (DE)**

- (72) Inventors:
- **CHAUX, Pascal**  
**1200 Brussels (BE)**
  - **LUITEN, Rosalie**  
**1200 Brussels (BE)**
  - **DEMOTTE, Nathalie**  
**1200 Brussels (BE)**
  - **DUFFOUR, Marie-Thérèse**  
**1200 Brussels (BE)**
  - **LURQUIN, Christophe**  
**1200 Brussels (BE)**
  - **TRAVERSARI, Catia**  
**20132 Milan (IT)**

(56) References cited:  
**WO-A-94/03205 WO-A-95/04542**  
**WO-A-95/21630 WO-A-97/26328**  
**WO-A-98/10780 WO-A-99/14326**  
**WO-A-99/45954**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 117 679 B9**

- REED D S ET AL: "CONSTRUCTION AND CHARACTERIZATION OF A RECOMBINANT ADENOVIRUS DIRECTING EXPRESSION OF THE MAGE-1 TUMOR-SPECIFIC ANTIGEN" INTERNATIONAL JOURNAL OF CANCER,US, NEW YORK, NY, vol. 72, no. 6, 17 September 1997 (1997-09-17), pages 1045-1055, XP002051672 ISSN: 0020-7136
- PLAEN DE E ET AL: "STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF 12 GENES OF THE MAGE FAMILY" IMMUNOGENETICS,DE,SPRINGER VERLAG, BERLIN, vol. 40, no. 5, 1 January 1994 (1994-01-01), pages 360-369, XP000614537 ISSN: 0093-7711
- MCEL RATH M J ET AL: "Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals." AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 10, 1994, pages S69-S72, XP009071835
- TOSO J F ET AL: "MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation." CANCER RESEARCH, vol. 56, pages 16-20, XP002197554
- HAMMOND S A ET AL.: "General method for the detection and in vitro expansion of equine cytolytic T lymphocytes." JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, pages 73-85, XP004146483
- RIDDELL S R ET AL: "Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression." JOURNAL OF IMMUNOLOGY, vol. 146, pages 2795-2804,

**Description****FIELD OF INVENTION**

**[0001]** The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant *Yersinia*, recombinant *Salmonella*, or recombinant viruses. The present invention further relates to isolated CTL clones that are specific for proteins of the MAGE family. Antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones are also provided.

**BACKGROUND**

**[0002]** An important facet of the immune response in a mammalian subject is the recognition by T cells of the complexes of the cell surface molecules, i.e., the complexes of peptides and HLA (human leukocyte antigens) or MHC (major histocompatibility complexes) molecules. These peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecules. See in this regard, Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10. The interaction between T cell and HLA/peptide complexes is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present. This mechanism is involved in the immune system response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities.

**[0003]** Most progressively growing neoplastic cells express potentially immunogenic tumor-associated antigens (TAAs), also called tumor rejection antigens (TRAs). A number of genes have been identified that encode tumor rejection antigen precursors (or TRAPs), which are processed into TRAs in tumor cells. Such TRAP-encoding genes include members of the MAGE family, the BAGE family, the DAGE/PRAME family, the GAGE family, the RAGE family, the SMAGE family, NAG, Tyrosinase, Melan-A/MART-1, gp 100, MUC-1, TAG-72, CA125, mutated proto-oncogenes such as p53, tumor suppressor genes such as p53, tumor associated viral antigens such as HPV16 E7. See, e.g., review by Van den Eynde and van der Bruggen (1997) in Curr. Opin. Immunol. 9:684-693, Sahin et al. (1997) in Curr. Opin. Immunol. 9:709-716, and Shawler et al. (1997) Advances in Pharmacology 40: 309-337, Academic Press, Inc., San Diego, California.

**[0004]** TRAs, like other antigenic epitopes, are presented at the surface of tumor cells by MHC molecules and have been shown to induce a CTL response *in vivo* and *in vitro*. See, for example, van der Bruggen et al. (1991) Science 254: 1643-1647. However, such TRA-expressing tumor cells do not provoke reliable anti-tumor immune responses *in vivo* that are capable of controlling the growth of malignant cells. Boon et al. (1992) Cancer Surveys 13: 23-37; T. Boon (1993) Int. J. Cancer 54: 177-180; T. Boon (1992) Advances Cancer Res. 58: 177-209. Thus, generation of CTL clones that recognize specific TRAs provides a powerful tool for tumor therapeutics. The identification of TRAs also allows the design of recombinant vaccines for the treatment of various pathological conditions.

**[0005]** The present invention discloses a procedure for isolating CTL clones. By following such procedure, novel CTL clones have been isolated that recognize specific antigenic peptides of proteins, which are recited in the claims. MHC molecules presenting these peptides have been identified as well.

Toso J. F. et al., Cancer Research, vol. 56, pp. 16-20 disclose MAGE-1 specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterisation and antigen-specific activation.

Mcelrath M. J. et al (Aids Research and Human Retroviruses, vol. 10, 1994, pp. S69-S72) disclose the evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.

Hammond S. A. et al. (Journal of Immunological Methods, vol. 213, pp. 73-85) discloses a general method for the detection and *in vitro* expansion of quine cytolytic T lymphocytes.

Riddell S. R. et al. (Journal of Immunology, vol. 146, pp. 2795-2804) discuss that Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

WO 97/26328 discloses an immunotherapy using cytotoxic T lymphocytes (CTL) which recognize a molecule presented by and HLA class I molecule on the surface of a cell characterized in that the cytotoxic T lymphocytes are

not derived from the patient.

WO 95/21630 discloses a method for identifying individuals suffering from a cellular abnormality.

None of the above documents discloses the CTLs and/or HLA molecules that present peptides disclosed herein.

## SUMMARY OF THE INVENTION

**[0006]** Disclosed are methods for isolating CTL clones from a blood sample.

**[0007]** The methods include successive steps of stimulating and testing lymphocytes with antigen presenting cells. Such methods, by employing different antigen presenting cells at different steps, significantly reduce non-specific CTL activities generated in the procedure and permit more efficient isolation of CTL clones.

**[0008]** Antigen presenting cells which are used in the methods can differ in cell type and/or in the expression system from which the antigen to be presented is derived. Cells which can be employed as antigen presenting cells in the present methods include professional and facultative antigen presenting cells. A preferred antigen presenting cell is an autologous dendritic cell, an autologous B cell transformed with EBV, or an activated T cell.

**[0009]** Antigen presenting cells can be modified by a variety of ways to effect the expression of an antigen of interest at the cell surface, preferably, by infection with a recombinant *Yersinia*, recombinant *Salmonella*, or recombinant viruses. Preferred recombinant viruses include vaccinia, canarypox virus, other pox viruses, adenovirus, herpes simplex virus, and retrovirus.

**[0010]** The protein against which CTL clones are generated can be a tumor associated protein, wherein the protein is a member of the MAGE family, in particular, MAGE-A1, MAGE-A3 and MAGE-A4.

**[0011]** The present invention relates to CTL clones isolated by using the methods disclosed herein.

**[0012]** In a preferred embodiment, the present invention provides isolated CTL clones that are specific for peptide/HLA complexes SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, respectively.

**[0013]** In a more preferred embodiment, the present invention provides isolated CTL clones LB1137 462/F3.2, LB1801 456/H7.11, LB1118 466/D3.31, LB 1801 456/H8.33, LB1137 H4.13, LB1841 526/F7.1 and LB1803 483/G8.4.

**[0014]** Furthermore, the specification discloses methods of identifying antigenic peptide epitopes of a protein by using CTL clones isolated following the methods described herein.

**[0015]** The present invention provides newly isolated antigenic peptides, DPARYEFLW (MAGE-A1 258-266) (SEQ ID NO: 42), GVDGREHTV (MAGE-A4 230-239) (SEQ ID NO: 44), SAFPTTINF (SEQ ID NO: 47) (MAGE-A1 62-70), AELVHFLLL (SEQ ID NO: 55) (MAGE-A3 114-122). Nucleic acid sequences encoding such peptides are also described.

**[0016]** In another embodiment, the present invention provides isolated peptide/HLA complexes, peptide SAYGEPRKL (SEQ ID NO: 2) complexed with HLA-Cw3, peptide DPARYEFLW (SEQ ID NO: 42) complexed with HLA-B53, peptide GVDGREHTV (SEQ ID NO: 44) complexed with HLA-A2, peptide SAFPTTINF (SEQ ID NO: 47) complexed with HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48) complexed with HLA-A28, AELVHFLLL (SEQ ID NO: 55) complexed with HLA-B40, and RVRFFFPSL (SEQ ID NO: 57) complexed with HLA-B7.

**[0017]** In another embodiment, cells expressing any of these peptide/HLA complexes are contemplated.

**[0018]** Still another embodiment of the invention provides pharmaceutical compositions which include any one of the isolated CTL clones, the antigenic peptides, the peptide/HLA complexes, and cells expressing the peptide/HLA complexes of the present invention.

**[0019]** In a further aspect, the present invention provides methods useful for diagnosing and treating cancer.

**[0020]** One embodiment of the present invention provides method of detecting in a sample from a subject, a pathological condition characterized by an abnormal expression of a peptide/HLA complex, by detecting the presence of cells abnormally expressing such complex in the subject, wherein said pathological condition is cancer.

**[0021]** Another embodiment of the present invention provides methods of detecting in a sample of a subject, the presence of cells abnormally expressing a peptide/HLA complex of the present invention by using an isolated CTL clone of the present invention which specifically recognizes such complex.

**[0022]** One embodiment of the present invention provides methods of diagnosing in a subject in vitro, a cancer characterized by an abnormal expression of a peptide/HLA complex, by detecting an increased frequency of CTL cells specific for such complex

**[0023]** Another embodiment of the present invention provides methods of detecting in a sample of a subject the presence of CTL cells specific for a peptide/HLA complex of the present invention by using an antigen presenting cell expressing such complex at the cell surface.

**[0024]** In still another embodiment, the present invention provides uses of peptide/HLA complexes, or uses of CTLs disclosed herein for the manufacture of a medicament for the manufacture of a medicament for treating a subject with

a pathological condition characterized by an abnormal expression of a peptide/HLA complex of the present invention by administering to the subject, a therapeutically effective amount of cells of a CTL clone specific for such complex, wherein the pathological condition is cancer.

**[0025]** Another embodiment provides uses as described above for the manufacture of a medicament for the treatment of a subject of a cancer characterized by an abnormal expression of a peptide/HLA complex of the present invention, by administering to the subject a therapeutically effective amount of the peptide.

**[0026]** Still another embodiment provides second medical uses for treating a cancer characterized by an abnormal expression of a peptide/HLA complex of the present invention, by modifying antigen presenting cells in vitro to effect a presentation of the peptide/HLA complex at the cell surface.

## BRIEF DESCRIPTION OF FIGURES

**[0027]**

**Figure 1** illustrates the plasmid map of the expression vector pMS111-MAGE-A1 (YopE<sub>130</sub>-MAGE-AI).

**Figure 2** (A) depicts the procedure for stimulating CTL 82/30 with EBV-transformed human B cells (HLA-AI) mixed with recombinant *Yersinia*; (B) depicts the quantitation of IFN-released by activated CTLs.

**Figure 3** depicts the specific recognition by CTL clone LB1137 462/F3.2 of a MAGE-A1 antigenic peptide presented by HLA-Cw3.

**Figure 4** depicts the specific recognition by CTL clone LB1801 456/H7.11 of a MAGE-A1 antigenic peptide presented by HLA-B53.

**Figure 5** depicts the specific recognition by CTL clone LB1137 H4.13 of a MAGE-A4 antigenic peptide presented by HLA-A2.

**Figure 6** depicts the MAGE-A4 nucleotide sequences (SEQ ID NO: 49) and the primers used in PCR as described in Example 9.

**Figure 7** depicts a MAGE-A1 peptide presented by HLA-Cw2 to CTL clone LB1118 466/D3.31.

**7A.** Lysis by CTL clone LB1118 466/D3.31 of autologous EBV-B cells infected with vaccinia-MAGE-A1. Target cells were infected for 2 hours at an MOI of 20, <sup>51</sup>Cr-labeled, and incubated with CTL clone LB1118 466/D3.31 for 4 hours. Targets infected with the parental vaccinia were used as a negative control.

**7B.** Stimulation of CTL clone LB1118 466/D3.31 by COS-7 cells that were transiently transfected with a MAGE-A1 cDNA and a cDNA encoding HLA-Cw2. One day after transfection, 1,500 CTL clone LB1118 466/D3.31 were added into microwells containing 1.5x10<sup>4</sup> transfected COS-7 cells. TNF production was estimated after overnight coculture by testing the toxicity of the supernatants for the TNF-sensitive cells of WEHI-164 clone 13.

**7C.** Lysis by CTL clone LB1118 466/D3.31 of autologous EBV-B cells incubated with synthetic peptide SAFPTTINF (SEQ ID NO: 47) (MAGE-A1<sub>62-70</sub>). Targets were <sup>52</sup>Cr-labeled and incubated for 4 hours with the CTL, at an effector-to-target ratio of 5:1, in the presence of the peptide at the concentrations indicated.

**7D.** Lysis of HLA-Cw2 tumor cell lines by CTL clone LB1118 466/D3.31. Target cells were <sup>51</sup>Cr-labeled and incubated for 4 hours with CTL clone LB1118 466/D3.31 at various effector-to-target ratios.

**Figure 8** depicts a MAGE-A1 peptide presented by HLA-A28 to CTL clone LB1801 456/H8.33.

**8A.** Lysis by CTL clone LB1801 456/H8.33 of autologous EBV-B cells infected with vaccinia-MAGE-A1. Target cells were infected for 2 hours at an MOI of 20, <sup>51</sup>Cr labeled, and incubated with CTL clone LB1801 456/H8.33 for 4 hours. Targets infected with the parental vaccinia were used as a negative control.

**8B.** Stimulation of CTL clone LB1801 456/H8.33 by COS-7 cells transiently transfected with a MAGE-A1 cDNA and a cDNA encoding HLA-A28. One day after transfection, 1,500 CTL clone LB1801 456/H8.33 were added into microwells containing 1.5x10<sup>4</sup> transfected COS-7 cells. TNF production was estimated after overnight coculture by testing the toxicity of the supernatants for the TNF-sensitive cells of WEHI-164 clone 13.

**8C.** Lysis by CTL clone LB1801 456/H8.33 of autologous EBV-B cells incubated with synthetic peptide EVYDGREH-SA (SEQ ID NO: 48) (MAGE-A1<sub>222-231</sub>). Targets were <sup>51</sup>Cr-labeled and incubated for 4 hours with CTL clone LB1801 456/H8.33, at an effector-to-target ratio of 5:1, in the presence of the peptide at the concentrations indicated.

**8D.** Lysis of HLA-A28 melanoma line by CTL clone LB1801 456/H8.33. Target cells were <sup>51</sup>Cr-labeled and incubated for 4 hours with CTL clone LB1801 456/H8.33 at various effector-to-target ratios.

**Figure 9.** A MAGE-A3 peptide is presented to CTL clone LB1841 526/F7.1 by HLA-B40.

**9A.** Lysis by CTL clone LB1841 526/F7.1 of autologous EBV-B cells infected with vaccinia-MAGE-A3.

**9B.** Stimulation of CTL clone LB1841 526/F7.1 by COS-7 cells transiently transfected with a MAGE-A3 cDNA and a cDNA encoding an HLA molecule as indicated.

**9C.** Lysis by CTL clone LB1841 526/F7.1 of autologous EBV-B cells incubated with synthetic peptide AELVHFLLL (SEQ ID NO: 55) (MAGE-A3<sub>114-122</sub>).

**9D.** Lysis of HLA-B40 melanoma cells by CTL clone LB1841 526/F7.1.

Figure 10. A MAGE-A1 peptide is presented to CTL clone LB1803 483/G8.4 by HLA-B7.

**10A.** Lysis by CTL clone LB1803 483/G8.4 of autologous EBV-B cells infected with vaccinia-MAGE-A1.

**10B.** Stimulation of CTL clone LB1803 483/G8.4 by COS cells transiently transfected with a MAGE-A1 cDNA and a cDNA encoding an HLA molecule as indicated.

**10C.** Lysis by CTL clone LB1803 483/G8.4 of autologous EBV-B cells incubated with synthetic peptide RVRFFFPSL (SEQ ID NO: 57) (MAGE-A1<sub>289-297</sub>).

**10D.** Lysis of HLA-B7 melanoma cells by CTL clone LB1803 483/G8.4.

## DETAILED DESCRIPTION OF THE INVENTION

**[0028]** Described are methods for isolating CTL clones. The methods include successive steps of stimulating and testing lymphocytes by using different antigen presenting cells at different steps.

**[0029]** The procedure to develop specific CTL clones *in vitro* has been described. Briefly, a blood sample containing T-cell precursors is taken from a mammal. PBLs are purified from such blood sample and are incubated with stimulator cells which express antigenic peptides complexed with the appropriate MHC molecule. Stimulator cells can be tumor cells (see, e.g., the United States Patent No. 5,342,774, Knuth et al. (Proc. Natl. Acad. Sci. USA 86: 2804-2808, 1989) and Van Den Eynde et al. (Int. J. Cancer 44: 634-640, 1989), or antigen presenting cells pulsed with defined peptides. Additional components, e.g., allogeneic feeder cells and cytokines, can be added into the incubation mixture. CTLs specific for antigens expressed at the surface of the stimulator cells will proliferate, and thus, will be enriched in the cell population as a result of the stimulation. CTL clones can be subsequently isolated by, e.g., limiting dilution. However, the approach using antigen presenting cells pulsed with defined peptides as stimulator cells, have sometimes generated CTLs that are unable to recognize the relevant tumor cells.

**[0030]** The present inventors have found that efficient isolation of CTL clones can be achieved by successive steps of stimulating and testing T cell precursors, using different antigen presenting cells at different steps. The methods of isolating CTL clones permit significant reduction of CTL activities generated toward non-specific molecules, e.g., molecules expressed from the backbone sequence of an expression vector.

**[0031]** By "different antigen presenting cells" it means that the antigen presenting cells may differ in cell type or in the expression system from which an antigen of interest being presented is derived.

**[0032]** "Antigen presenting cells" as referred herein, express at least one class I or class II MHC determinant and may include those cells which are known as professional antigen-presenting cells such as macrophages, dendritic cells and B cells. Other professional antigen-presenting cells include monocytes, marginal zone Kupffer cells, microglia, Langerhans' cells, interdigitating dendritic cells, follicular dendritic cells, and T cells. Facultative antigen-presenting cells can also be used according to the present invention. Examples of facultative antigen-presenting cells include activated T cells, astrocytes, follicular cells, endothelium and fibroblasts. As used herein, "antigen-presenting cells" encompass both professional and facultative types of antigen-presenting cells.

**[0033]** The antigen presenting cells can be isolated from tissue or blood samples (containing peripheral blood mononuclear cells) obtained from a mammal such as human. Cell lines established from such samples may also be used. Procedures for establishing cell lines are well known in the art. Certain cell lines may be obtained directly from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland, 20852-1776. Both normal and malignant cells can be employed.

**[0034]** Preferably, the MHC determinants expressed by the antigen presenting cells are compatible with those expressed by the mammal from which the sample containing T cell precursors is taken. More preferably, autologous antigen presenting cells or cell lines established therefrom are employed. Non-autologous cells may be used as long as the MHC determinants expressed by such cells are compatible, either naturally, by way of transfection or other means that are appropriate. One skilled in the art is also familiar with the methods for determining whether the MHC molecules expressed by an antigen presenting cell are compatible with those of the mammal subject involved, such as well known HLA-typing procedures. See general teachings by Coligan et al. (1994) Current Protocols in Immunology John Wiley & Sons Inc: New York, New York.

**[0035]** Preferred antigen presenting cells are autologous dendritic cells, autologous B cells transformed with EBV, and autologous T cell activated by PHA.

**[0036]** Further, according to the present invention, antigen presenting cells used in the present methods can also differ in the expression system from which an antigen of interest is derived. More specifically, the antigen presenting cells can be modified in various ways to effect the expression of an antigen at the cell surface. For example, an antigen presenting cell can be infected with a recombinant *Yersinia*, a recombinant *Salmonella*, or a recombinant virus. In each case, the recombinant microorganism encodes a protein from which the peptide antigen presented is derived.

**[0037]** The protein expressed from any of these expression systems is processed in the antigen presenting cells into small peptides, which are then complexed with the appropriate MHC molecules and presented at the cell surface. In the present invention, peptides that are complexed with MHC molecules and presented at the cell surface are also referred

to as "antigens".

**[0038]** The term "*Yersinia*" as used herein includes all species of *Yersinia*, including *Yersinia enterocolitica*, *Yersinia pseudotuberculosis* and *Yersinia pestis*. The term "recombinant *Yersinia*" used herein refers to *Yersinia* genetically transformed with an expression vector. The term "delivery" used herein refers to the transportation of a protein from a *Yersinia* to an antigen presenting cell, including the steps of expressing the protein in the *Yersinia*, secreting the expressed protein(s) from such *Yersinia* and translocating the secreted protein(s) by such *Yersinia* into the cytosol of the antigen presenting cell.

**[0039]** *Yersinia* for use in expressing and delivering the protein of interest are preferably mutant *Yersinia* that are deficient in producing functional effector proteins.

**[0040]** A preferred mutant *Yersinia* strain for use in expressing and delivering the protein of interest is a quintuple-mutant *Yersinia* strain in which all the effector-encoding genes are mutated such that the resulting *Yersinia* no longer produce any functional effector proteins. Such quintuple-mutant *Yersinia* strain is designated as *yopEHOMP* for *Y. enterocolitica* or *yopEHAMJ* for *Y. pseudotuberculosis*. One example of such *yopEHOMP* strain is *Y. enterocolitica* MRS40(pABL403).

**[0041]** An antigenic protein of interest can be cloned into a yersinia expression vector Ffr used in combination with a mutant *Yersinia* for delivery of the protein into antigen presenting cells. Such a vector is characterized by (in the 5' to 3' direction) a promoter, a first nucleic acid sequence encoding a delivery signal, a second nucleic acid sequence fused thereto coding for the protein to be delivered and other sequences that may be appropriate (e.g., a polyadenylation signal).

**[0042]** The promoter of the expression vector is preferably from a *Yersinia* virulon gene. A "*Yersinia* virulon gene" refers to genes on the *Yersinia* pYV plasmid, the expression of which is controlled both by temperature and by contact with a target cell. See review by Cornelis et al. (1997). Such genes include genes coding for elements of the secretion machinery (the YSC genes), genes coding for translocators (*YopB*, *YopD*, and *LcrV*), genes coding for the control elements (*YopN* and *LcrG*), and genes coding for effectors (*YopE*, *YopH*, *YopO/YpkA*, *YopM* and *YopP/YopJ*). Preferably, the promoter is from an effector-encoding gene selected from any one of *YopE*, *YopH*, *YopO/YpkA*, *YopM* and *YopP/YopJ*. More preferably, the promoter is from *YopE*.

**[0043]** Further, a first DNA sequence coding for a delivery signal is operably linked to the promoter. "A delivery signal", as described hereinabove, refers to a polypeptide which can be recognized by the secretion and translocation system of *Yersinia* and therefore directs the secretion and translocation of a protein into an antigen presenting cell. Such polypeptide is from an effector protein including *YopE*, *YopH*, *YopO/YpkA*, *YopM*, and *YopP/YopJ*, and preferably, *YopE*. More preferably, the effector protein is *YopE* of *Yersinia enterocolitica*.

**[0044]** One skilled in the art is familiar with the methods for identifying the polypeptide sequences of an effector protein that are capable of delivering a protein. For example, one such method is described by Sory et al. (1994). Examples of such delivery signal polypeptides include from *Y. enterocolitica*: *YopE*<sub>130</sub> (the N-terminal 130 amino acids of *YopE*), *YopE*<sub>50</sub>, *YopM*<sub>100</sub> and *YopH*<sub>71</sub>.

**[0045]** The yersinia expression vectors may be transformed into *Yersinia* by a number of known methods which include, but are not limited to, electroporation, calcium phosphate mediated transformation, conjugation, or combinations thereof. For example, a vector can be transformed into a first bacteria strain by a standard electroporation procedure. Subsequently, such a vector can be transferred from the first bacteria strain into *Yersinia* by conjugation, a process also called "mobilization". *Yersinia* transformant (i.e., *Yersinia* having taken up the vector) may be selected, e.g., with antibiotics. These techniques are well known in the art. See, for example, Sory et al. (1994).

**[0046]** The delivery of a protein from a recombinant *Yersinia* into the cytosol of an antigen presenting cell can be effected by contacting an antigen presenting cell with a recombinant *Yersinia* under appropriate conditions. Multiple references and techniques are available for those skilled in the art regarding the conditions for inducing the expression and translocation of virulon genes, including the desired temperature, Ca<sup>++</sup> concentration, manners in which *Yersinia* and target cells are mixed, and the like. See, for example, Cornelis, Cross talk between *Yersinia* and eukaryotic cells, Society for General Microbiology Symposium, 55; Mocrae, Saunders, Smyth, Stow (eds), Molecular aspects of host-pathogen interactions, Cambridge University Press, 1997. The conditions may vary depending on the type of eukaryotic cells to be targeted, e.g.: the conditions for targeting human epithelial carcinoma Hela cells (Sory et al. (1994)); the conditions for targeting mouse thymoma or melanoma cells (Starnbach et al. (1994) J. Immunol. 153: 1603); and the conditions for targeting mouse macrophages (Boland et al. (1996)). Such variations can be addressed by those skilled in the art using conventional techniques.

**[0047]** Those skilled in the art can also use a number of assays to determine whether the delivery of a fusion protein is successful. For example, the fusion protein may be labeled with an isotope or an immunofluoresceine, or detected by an immunofluoresceine conjugated antibody, as disclosed by Rosqvist et al. (1994) EMBD J. 13: 964. The determination can also be based on the enzymatic activity of the protein being delivered, e.g., the assay described by Sory et al. (1994). The determination can also be based on the antigenicity of the protein being delivered. For example, the delivery of a MAGE-A1 protein into EBV-transformed human B cells can be detected by the recognition of such targeted B cells by CTL cells specific for MAGE-A1 epitopes. Such CTL recognition, in turn, may be detected by a number of assays including

assaying the secretion of IFN- $\gamma$  from the activated CTLs or Cr<sup>51</sup> release from lysed target cells. Methods such as Western-blot analysis using antibodies specific against the protein being delivered, PCR in situ hybridization, or ELISPOT (Mabtech AB, Sweden) may also be employed for such determination. See, e.g., W. Herr et al. (1997) J. Immunol. Methods 203: 141-152 and W. Herr et al. (1996) J. Immunol. Methods 191: 131-142.

**[0048]** The antigenic protein of interest can also be expressed from a recombinant Salmonella. For example, avirulent strains of *Salmonella typhimurium* can be used as antigen delivery vectors. It is known in the art that antigenic epitopes, such as viral epitopes can be successfully delivered to the host cell cytosol by using the type III protein secretion system of *S. typhimurium*. See, e.g., Russmann et al. (1998) 281: 565-568.

**[0049]** The expression of a protein of interest in the antigen presenting cell can also be effected by infection of the antigen presenting cells with a recombinant virus. In particular, the specification describes recombinant viruses of vaccinia, canarypox virus, other pox viruses, adenovirus, herpes simplex virus, retrovirus and any other viruses that are appropriate.

**[0050]** A preferred strain of vaccinia for use is the WR strain (Panicali et al. (1981), J. Virol. 37: 1000-1010). The nucleotide sequence coding for the protein of interest can be operably linked to a promoter, such as an vaccinia promoter H6, and inserted into a vaccinia vector, thereby generating a donor plasmid. Vaccinia vectors which can be employed for generating adeno-plasmids are available to those skilled in the art and are described in, e.g., U.S. Patent No. 4,769,330. Recombinant WR strains of vaccinia can be generated by using a donor plasmid via *in vivo* recombination, following well-known procedures. See, e.g., Perkins et al., J. Virol. 63: 3829-3936 (1989).

**[0051]** A preferred strain of canarypox virus for use in the present invention is ALVAC (Cox et al. (1993), Virology 195: 845-850). The nucleotide sequence coding for the protein of interest can be operably linked to a promoter, such as an vaccinia promoter H6, and inserted into an ALVAC vector to create a donor plasmid. Multiple ALVAC vectors are available to one skilled in the art and are described by, e.g., U.S. Patent No. 5,756,106; Cox et al. (1993) Virology 195: 845-850; Tartaglia et al. (1993) J. Virology 67: 2370-2375; and Taylor et al. (1992) Virology 187: 321-328. Such donor plasmid can be used to generate recombinant ALVAC viruses via *in vivo* recombination. See, e.g., Cox. et al. (1993); Tartaglia et al. (1993) and Taylor et al. (1992).

**[0052]** Those skilled in the art can also generate recombinant adenoviruses for expressing the protein of interest as described in, e.g., Example 5 hereinafter.

**[0053]** A nucleotide sequence encoding the antigenic protein of interest can be cloned into the various expression vectors as described above. There is no particular limitation in the protein that can be employed in the instant methods for isolating CTL clones.

**[0054]** The term "protein" as used herein refers to naturally occurring proteins as well as artificially engineered proteins, or parts thereof. The term "part of a protein" includes a peptide fragment of a protein that is of sufficient length to be antigenic. Preferably, such a fragment consists of at least 8 or 9 amino acids. "Artificially engineered proteins" as used herein refer to non-naturally occurring proteins, e.g., modified forms of non-naturally occurring proteins, or fusion of two or more naturally occurring proteins or parts thereof, which are also referred to as polytopes (in-frame fusion of two or more epitopes) as exemplified by Thompson et al. (1995) in Proc. Natl. Acad. Sci. USA 92: 5845-5849.

**[0055]** The present invention contemplates, in particular, MAGE proteins.

**[0056]** A "tumor associated protein" refers to a protein that is specifically expressed in tumors or expressed at an abnormal level in tumors relative to normal tissues, that are members of the MAGE family. Members of the MAGE family include, but are not limited to, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A11. See, e.g., review by Van den Eynde and van der Bruggen (1997) in Curr. Opin. Immunol. 9: 684-693, Sahin et al. (1997) in Curr. Opin. Immunol. 9: 709-716, and Shawler et al. (1997). These proteins have been shown to associate with certain tumors such as melanoma, lung cancer, prostate cancer, breast cancer, renal cancer and others.

**[0057]** A number of known antigenic proteins from pathogens are also described. The pathogens can include viruses, bacteria, parasites and fungi. Specific examples of antigenic proteins characteristic of a pathogen include the influenza virus nucleoprotein (residues 218-226, as set forth in F. et al. (1997) J. Virol. 71: 2715-2721) antigens from Sendai virus and lymphocytic choriomeningitis virus (see, An et al. (1997) J. Virol. 71: 2292-2302), the B1 protein of hepatitis C virus (Bruna-Romero et al. (1997) Hepatology 25: 470-477), the virus envelope glycoprotein gp 160 of HIV (Achour et al. (1996) J. Virol. 70: 6741-6750), amino acids 252-260 or the circumsporozoite protein of *Plasmodium berghei* (Allsopp et al. (1996) Eur. J. Immunol. 26: 1951-1958), the influenza A virus nucleoprotein (residues 366-374, Nomura et al. (1996) J. Immunol. Methods 193: 4149), the listeriolysin O protein of *Listeria monocytogenes* (residues 91-99, An et al. (1996) Infect. Immun. 64: 1685-1693), the E6 protein (residues 131-140, Gao et al. (1995) J. Immunol. 155: 5519-5526) and E7 protein (residues 21-28 and 48-55, Bauer et al. (1995) Scand. J. Immunol. 42: 317-323) of human papillomavirus type 16, the M2 protein of respiratory syncytial virus (residues 82-90 and 81-95, Hsu et al. (1995) Immunology 85: 347-350), the herpes simplex virus type 1 ribonucleotide reductase (see, Salvucci et al. 1995) J. Gen. Virol. 69: 1122-1131) and the rotavirus VP7 protein (see, Franco et al. (1993) J. Gen. Virol. 74: 2579-2586), *P. falciparum* antigens (causing malaria) and hepatitis B surface antigen (Gilbert et al. (1997) Nature Biotech. 15: 1280-1283).

**[0058]** A number of short antigenic peptides can also be employed. One skilled in the art can readily determine the



length of the fragments required to produce immunogenic peptides. Alternatively, the skilled artisan can also use coding sequences for peptides that are known to elicit specific T cell responses (either CD4<sup>+</sup> or CD8<sup>+</sup> T cells), such as tumor-associated antigenic peptides (TAA, also known as TRAs for tumor rejection antigens) as disclosed by U.S. Patent No. 5,462,871, U.S. Patent No. 5,558,995, U.S. Patent No. 5,554,724, U.S. Patent No. 5,585,461, U.S. Patent No. 5,591,430, U.S. Patent No. 5,554,506, U.S. Patent No. 5,487,974, U.S. Patent No. 5,530,096, U.S. Patent No. 5,519,117. Examples of TRAs are provided in Table 1. See also review by Van den Eynde and van der Bruggen (1997) and Shawler et al. (1997). Antigenic peptides of a pathogen origin can also be used, such as those disclosed by Gilbert et al. (1997).

**Table 1: Exemplary Antigens**

Gene	MHC	Peptide	Position	SEQ ID NO:
MAGE-A1	HLA-A1	EADPTGHSY	161-169	1
	HLA-Cw16	SAYGEPRKL	230-238	2
MAGE-A3	HLA-A1	EVDPIGHLV	168-176	3
	HLA-A2	FLWGPRALV	271-279	4
	HLA-B44	MEVDPIGHLV	167-176	5
BAGE	HLA-Cw16	AARAVFLAL	2-10	6
GAGE-1,2	HLA-Cw16	YRPRPRRY	9-16	7
RAGE	HLA-B7	SPSSNRIRNT	11-20	8
GnT-V	HLA-A2	VLPDVFIRC(V)	2-10/11	9
MUM-1	HLA-B44	EEKLIWLF	exon 2/intron	10
		EEKLSWLF (wild type)		11
CDK4	HLA-A2	ACDPHSGHFV	23-32	12
		ARDPHSGHFV (wild type)		13
$\beta$ -catenin	HLA-A24	SYLDSGIHF	29-37	14
		SYLDSGIHS (wild type)		15
Tyrosinase	HLA-A2	MLLAVLYCL	1-9	16
	HLA-A2	YMNGTMSQV	369-377	17
	HLA-A2	YMDGTMSQV	369-377	18
	HLA-A24	AFLPWHRLF	206-214	19
	HLA-B44	SEIWRDIDF	192-200	20
	HLA-B44	YEIWRDIDF	192-200	21
	HLA-DR4	QNILLSNAPLGPQFP	56-70	22
	HLA-DR4	DYSYLQDSDPDSFQD	448-462	23
Melan-A <sup>MART-1</sup>	HLA-A2	(E)AAGIGILTV	26/27-35	24
	HLA-A2	ILTVILGVL	32-40	25
gp100 <sup>Pmel117</sup>	HLA-A2	KTWGQYWQV	154-162	26
	HLA-A2	ITDQVPFSV	209-217	27
	HLA-A2	YLEPGPVTA	280-288	28
	HLA-A2	LLDGTATLRL	457-466	29
	HLA-A2	VLYRYGSFSV	476-485	30
DAGE	HLA-A24	LYVDSLFFL	301-309	31
MAGE-A6	HLA-Cw16	KISGGPRISYPL	292-303	32

**[0059]** As described herein above, sequences coding for a full-length naturally occurring protein, a part of a naturally occurring protein, combinations of parts of a naturally occurring protein, or combinations of different naturally occurring proteins or parts from different proteins, may all be employed to be cloned into the expression vectors as described hereinabove.

**[0060]** The specification further discloses recombinant expression vectors which can be employed in the methods described herein, including recombinant yersinia expression vectors, e.g., pMS111-YopE<sub>130</sub>-MAGE-A1 and PMS111-YopE<sub>130</sub>-MAGE-A4; recombinant vaccinia vectors, e.g., WR-MAGE-A1 and WR-MAGE-A4; recombinant canarypox viral vectors, e.g., ALVAC-MAGE-A1; recombinant adenoviral vectors, e.g., adeno-MAGE-A4; and retroviral vectors, e.g., M1-CSM.

**[0061]** To carry out the methods, a sample containing T-cell precursors is obtained from a subject, typically, a blood sample from a human subject. The subject can be a cancer patient or an individual without cancer. The sample may be treated to concentrate T-cell precursors prior to stimulation.

**[0062]** The sample is contacted with a first antigen presenting cell expressing a protein, along with any other materials that may be appropriate, such as lymphokines. Upon contact, specific T-cell precursors are activated and begin to proliferate.

**[0063]** Cells in the sample are subsequently tested by contacting the cells with a second antigen presenting cell expressing the protein. The sample can be first diluted and distributed into microwells such that individual cells can be separately tested. CTL Cells which are specific for the protein, or "responding CTLs", can be identified and selected by a variety of standard assays such as a <sup>51</sup>Cr release assay, a IFN- $\gamma$  secretion assay, or a TNF production assay.

**[0064]** CTL cells thus selected are subject to at least one additional cycle of stimulation and testing steps.

**[0065]** The antigen presenting cells used at one step can differ from the cells used in a subsequent step, either in cell type or in the expression system from which the protein is expressed.

**[0066]** For testing the specificity of CTL responses after stimulation, antigen presenting cells of a type that expresses high amounts of class I HLA molecules are preferred, e.g., EBV-transformed B cells.

**[0067]** Preferably, one of the expression systems used by the antigen presenting cell at one step (either stimulation or testing), is different from at least one of the other expression systems used in another step.

**[0068]** More preferably, the antigen presenting cells used at a stimulation step employ an expression system different from that used in the immediately following testing step.

**[0069]** The specification discloses examples of combinations of different antigen presenting cells which can be used for isolating specific CTL clones. CD8<sup>+</sup> T lymphocytes obtained from an individual can be stimulated in microwells with autologous monocyte-derived dendritic cells infected with a recombinant ALVAC canarypoxvirus encoding a protein of interest. After several times of stimulation, an aliquot of each microculture can then be tested for specific lysis of autologous EBV-B cells infected with a recombinant Vaccinia encoding the protein of interest. The positive microcultures can then be diluted and stimulated again with autologous EBV-B cells infected with a recombinant *Yersinia* encoding the protein of interest. Specific clones can be detected and thus isolated by testing for specific lysis of autologous EBV-B cells infected with a recombinant Vaccinia encoding the protein of interest. Thus, the combination of antigen presenting cells used in the foregoing procedure can be characterized as dendritic-ALVAC/EBV-B-Vaccinia/EBV-B-Yersinia/EBV-B-Vaccinia. Additional preferred combinations of antigen presenting cells which can be used in the present methods include: dendritic-Adeno/EBV-B-Vaccinia/EBV-B-Yersinia/EBV-B-Vaccinia, dendritic-ALVAC/EBV-B-Vaccinia/T cell-retroviral/EBV-B-Vaccinia.

**[0070]** The present invention contemplates CTL clones isolated by using the methods disclosed herein.

**[0071]** Disclosed are methods for identifying antigenic peptide epitopes of a protein. According to such method, CTL clones that recognize certain antigenic epitopes of a protein are isolated using the disclosed method of isolating CTL clones, as described hereinabove. Such clones can then be used to identify the specific antigenic peptides as well as the presenting HLA molecules, using a variety of well-known procedures, for example, procedures described in Examples 7-11.

**[0072]** According to the methods described herein, the identification of an antigenic peptide epitope of a protein is based on the capacity of the peptide/HLA complex, at the surface of an antigen presenting cell, to activate the specific CTLs. The antigenic peptide epitopes thus identified likely represent the epitopes that are well processed and adequately expressed at the cell surface *in vivo*. By using such method, antigenic peptide epitopes from proteins of the MAGE family have been identified; namely, MAGE-A1 peptide 230-238 (presented by HLA-Cw3 and recognized by clone LB1137 462/F3.2), MAGE-A1 peptide 258-266 (presented by HLA-B53 and recognized by clone LB1801 456/H7.11), MAGE-A1 peptide 62-70 (presented by HLA-Cw2 and recognized by clone LB 1118 466/D3.31), MAGE-A1 peptide 222-231 (presented by HLA-A28 and recognized by clone LB1801 456/H8.33), MAGE-A1 peptide 289-297 (presented by HLA-B7 and recognized by clone LB1803 483/G8.4), a MAGE-A3 peptide 114-122 (presented by HLA-B40 and recognized by clone LB1841 526/F7.1), and a MAGE-A4 peptide 230-239 (presented by HLA-A2 and recognized by clone LB1137 H4.13). See **Table 2**. Among these, MAGE-A1 peptide 230-238 (SAYGEPRKL (SEQ ID NO: 2)) has been previously identified, but was found therein to be presented by a different HLA molecule, HLA-Cw16 (U.S. Patent No. 5,558,995).

TABLE 2

GENE	POSITION	PEPTIDE	MHC	CTL	SEQ ID
MAGE-A1	230-238	SAYGEPRKL	HLA-Cw3	LB1137 462/F3.2	2
MAGE-A1	258-266	DPARYEFLW	HLA-B53	LB1801 456/H7.11	42
MAGE-A4	230-239	GVYDGREHTV	HLA-A2	LB1137 H4.13	44
MAGE-A1	62-70	SAFPTTINF	HLA-Cw2	LB1118 466/D3.31	47
MAGE-A1	222-231	EVYDGREHSA	HLA-A28	LB1801 456/H8.33	48
MAGE-A3	114-122	AELVHFLLL	HLA-B40	LB1841 526/F7.1	55
MAGE-A1	289-297	RVRFFFPSL	HLA-B7	LB1803 483/G8.4	57

**[0073]** Accordingly, another embodiment of the present invention provides isolated CTL clones that are specific for peptide/HLA complexes SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVYDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, respectively.

**[0074]** In a preferred embodiment, the present invention provides isolated CTL clones LB1137 462/F3.2, LB1801 456/H7.11, LB1118 466/D3.31, LB1801 456/H8.33, LB1137 H4.13, LB1841 526/F7.1 and LB1803 483/G8.4.

**[0075]** In another embodiment, the present invention is directed to the newly isolated antigenic peptides, namely, DPARYEFLW (SEQ ID NO: 42) (MAGE-A1 258-266), GVYDGREHTV (SEQ ID NO: 44) (MAGE-A4 230-239), SAFPTTINF (SEQ ID NO: 47) (MAGE-A1 62-70), AELVHFLLL (SEQ ID NO: 55) (MAGE-A3 114-122). Nucleic acid sequences encoding these peptides are also described.

**[0076]** Another embodiment of the present invention is directed to the isolated peptide/HLA complexes of the present invention. Specifically, the present invention provides isolated complex of peptide SAYGEPRKL (SEQ ID NO: 2) and HLA-Cw3, complex of peptide DPARYEFLW (SEQ ID NO: 42) and HLA-B53, complex of peptide GVYDGREHTV (SEQ ID NO: 44) and HLA-A2, complex of peptide SAFPTTINF (SEQ ID NO: 47) and HLA-Cw2, complex of peptide EVYDGREHSA (SEQ ID NO: 48) and HLA-A28, complex of AELVHFLLL (SEQ ID NO: 55) and HLA-B40, and complex of RVRFFFPSL (SEQ ID NO: 57) and HLA-B7.

**[0077]** Once the presenting HLA molecule for an antigenic peptide epitope has been ascertained, a complex of the peptide and the HLA molecule can be made by a variety of methods. For example, the HLA molecule can be produced and isolated by any appropriate recombinant expression system, e.g., an *E. coli*-based expression system. Peptides can be made by, e.g., chemical synthesis or recombinant expression. The peptides and the HLA molecules can then be mixed *in vitro* under conditions that favor the formation of the HLA/peptide complexes. Such conditions are well known in the art. See, e.g., Garboczi et al. (Proc. Natl. Acad. Sci. USA 89: 3429-3433, 1992 and Altman et al. (Science 274: 94-96, 1996).

**[0078]** The present invention further contemplates cells expressing any of the instant peptide/HLA complexes at the cell surface. Such cells can be made using any antigen presenting cells that are appropriate including cell lines (e.g., COS cells, CHO cells and the like), and by, e.g., peptide loading, or cotransfection as described in the Examples of the present disclosure.

**[0079]** In another embodiment, the present invention contemplates pharmaceutical compositions which include any one of the isolated CTL clones, the isolated antigenic peptides, the isolated peptide/HLA complexes, the antigen presenting cells expressing peptide/HLA complexes of the present invention, or combinations thereof.

**[0080]** The pharmaceutical compositions of the present invention can include other substances such as cytokines, adjuvants and pharmaceutically acceptable carriers. As used herein, a therapeutically acceptable carrier includes any and all solvents, including water, dispersion media, culture from cell media, isotonic agents and the like that are non-toxic to the host. Preferably, it is an aqueous isotonic buffered solution with a pH of around 7.0. The use of such media and agents in therapeutic compositions is well known in the art. Supplementary active ingredients can also be incorporated into the compositions.

**[0081]** In a further aspect of the present invention, the isolated CTL clones, the isolated antigenic peptides, the cells expressing the peptide/HLA complexes of the present invention are employed in various methods for diagnosing a pathological condition in a subject, preferably, a human subject.

**[0082]** The pathological conditions contemplated by the present invention include tumors.

**[0083]** The term "abnormal expression" as used herein refers to an expression that is not present in normal cells or an expression that is present in normal cells at a significantly lower level. In the present invention, "an abnormal expression" can also be used to refer to an unusual processing of a protein which gives rise to an antigenic epitope that is not

presented at the surface of normal cells.

**[0084]** In one embodiment, the present invention provides methods of detecting in a sample of a subject, a cancer characterized by an abnormal expression a peptide/HLA complex, by detecting the presence of cells abnormally expressing such complex.

**[0085]** In another embodiment, the present invention provides methods of detecting in a subject is sample the presence of cells abnormally expressing a peptide/HLA complex of the present invention, by using an isolated CTL clone specific for such complex.

**[0086]** A sample containing the cells suspected to be abnormal that has been obtained from the subject by, e.g., tissue biopsy is then contacted with a CTL clone of the present invention. The presence of the abnormal cells can be determined by measuring the activity of the CTL clone (i.e., CTL response) using standard assays such as <sup>51</sup>Cr release, IFN-gamma secretion, or TNF production.

**[0087]** In another embodiment, the present invention provides methods for detecting in a sample obtainable from a subject, the presence of CTL cells specific for an isolated peptide/HLA complex of the present invention. More specifically, a blood sample from the subject is contacted with cells expressing the specific peptide/HLA complexes. The presence of CTL cells specific for the complex can be detected by any of the approaches described hereinabove, e.g., the lysis of the cells expressing the specific peptide/HLA complexes measurable by a standard <sup>51</sup>Cr release assay.

**[0088]** Furthermore, the frequency of CTLs specific for a peptide/HLA complex can be assessed by, e.g., limiting dilution analysis or tetramer assays. By comparing with a normal individual, an increased frequency of CTLs specific for a peptide/HLA complex in an individual, is indicative of a cancer characterized by an abnormal expression of the complex. Accordingly, the present invention contemplates methods of diagnosing a cancer characterized by an abnormal expression of a peptide/HLA complex by detecting an increased frequency of CTLs specific for such peptide/HLA complex.

**[0089]** In a further aspect of the present invention, the isolated CTL clones, the isolated antigenic peptides, the cells expressing the peptide/HLA complexes of the present invention are used for the preparation of medicaments for treating a pathological condition in a subject, preferably, a human subject, wherein said condition is cancer.

**[0090]** The term "treating" is used to refer to alleviating or inhibiting a pathological condition, e.g., inhibiting tumor growth or metastasis, reducing the size of a tumor by e.g., eliciting an immune response.

**[0091]** In one embodiment, an isolated CTL clone of the present invention can be used for the preparation of a medicament, which is administered in a therapy regimen of adoptive transfer, to a subject suffering a cancer characterized by an abnormal expression of the peptide/HLA complex that is specifically recognized by such CTL clone. See teachings by Greenberg (1986) J. Immunol. 136 (5): 1917; Riddel et al. (1992) Science 257: 238; Lynch et al. (1991) Eur. J. Immunol. 21: 1403; and Kast et al. (1989) Cell 59: 603 for adoptive transfer. CTLs, by lysing the cells abnormally expressing such antigens, can alleviate or treat the cancer at issue, such as a tumor.

**[0092]** In another embodiment, the present invention provides uses of medicaments for treating a subject suffering from cancer characterized by an abnormal expression of a peptide/HLA complex, by administering the isolated peptides, or the peptide/HLA complexes, to the subject. The cancer can be alleviated by, e.g., specific immune responses elicited due to the administered peptides or peptide/HLA complexes.

**[0093]** In another embodiment of the present invention, a subject suffering from cancer characterized by an abnormal expression of a peptide/HLA complex of the present invention can be treated by antigen presenting cells obtained from the subject, in vitro modifying such cells to effect a presentation of the peptide/HLA complex at the cell surface, and then using such "loaded" cells for the preparation of a medicament for the treatment of cancer. The modification can be achieved by transfecting the isolated antigen presenting cells with any appropriate expression vectors encoding the peptide or the full-length protein, or by loading the cells with the peptides at issue following a peptide loading procedure as described by, e.g., Nestle et al. (Nature Medicine 4: 328-332, 1998).

**[0094]** For treatment purposes, the isolated CTL clones, the peptides or the peptide/HLA complexes, or the cells expressing the peptide/HLA complexes can be used as a medicament administered to a subject alone or in combination with other appropriate materials, such as cytokines, adjuvants or a pharmaceutical carriers. The amount of the CTL cells, the peptides, the peptide/HLA complexes, or cells expressing the complexes, can be determined according the condition of the subject.

**[0095]** For additional teachings of diagnostic and therapeutic uses of isolated CTLs and peptide/HLA complexes, see, e.g., Thomson et al. (1995) PNAS 92: 5845; Altman et al. (1996) Science 274: 94-96; Dunbar et al. (1998) Current Biology 8: 413-416; Greenberg et al. (1986) J. Immunol. 136: 1917; and Kast et al. (1989) Cell 59: 603-614.

**[0096]** The present invention is further illustrated by the following examples.

**[0097]** Terms and expressions which have been employed in the present disclosure are used as terms of description.

## EXAMPLE 1

GENERATION OF RECOMBINANT *YERSINIA* AND TARGETING EBV-TRANSFORMED B CELLS WITH RECOMBINANT *YERSINIA*

## Strains, Plasmids and Growth Conditions

**[0098]** *Y. enterocolitica* strain E40 (pYV40), MRS40(pYV40), which is the isogenic ampicillin sensitive derivative of E40(pYV40), and their various non-polar mutants (Sory et al. (1995), Proc. Natl Acad. Sci. USA 92: 11998-12002). Plasmids are listed in **Table 3**. Bacteria were grown in Brain Heart Infusion (BHI) (Difco, Detroit, Michigan). After overnight preculture, bacteria were diluted 1/20 in fresh BHI, allowed to grow for 30 minutes at room temperature, and synthesis of the Yop virulon was induced by incubation for 150 minutes at 37°C before infection.

Construction of the Polymutant *Yersinia* Strains

**[0099]** To construct the *yopHOPEM* polymutant strain, the *yopE*, *yopH*, *yopO*, *yopM* and *yopP* genes were successively knocked out by allelic exchange in the MRS40 strain using the suicide vectors pMRS101 and pKNG101. See, K. Kaniga et al. (1991) "A wide-host range suicide vector for improving reverse genetics in gram-negative bacteria: inactivation of the *blaA* gene of *Yersinia enterocolitica*" Gene 109: 137-141 and M.R. Sarker et al. (1997) "An improved version of suicide vector pKNG101 for gene replacement in Gram-negative bacteria" Mol. Microbiol. 23: 409-411. The various deletions are described in Table 2 in the "suicide vectors and mutators" section. The *YopE* gene was first mutated using the mutator pPW52 (see, P. Wattiau et al. (1993) "SycE, a chaperone-like protein of *Yersinia enterocolitica* involved in the secretion of YopE" Mol. Microbiol. 8: 123-131), giving strain MRS40(pAB4052). Mutation of the *YopH* gene in this strain with the mutator pAB31 (see, S.D. Mills et al. (1997) "Yersinia enterocolitica induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein" Proc. Natl. Acad. Sci. USA 94: 12638-12643) gave the double *yopEH* mutant MRS40(pAB404). The triple *yopEHO* mutant MRS40(pAB405) was then obtained by allelic exchange with the mutator pAB34 (see, S.D. Mills et al., 1997). The *YopP* gene was then mutated with mutator pMSK7 (see S.D. Mills et al. (1997)), leading to the *yopEHOP* mutant MRS40(pMSK46). The *yopHOPEM* strain MRS40(pABL403) was finally obtained by allelic exchange with the *yopM* mutator pAB38 (see, S.D. Mills et al., 1997).

Table 3: Plasmids

Plasmids	Relevant Characteristics	References
pABL403	pYV40 <i>yopE</i> <sub>21</sub> , <i>yopH</i> Δ <sup>1-352</sup> <i>yopO</i> Δ <sup>65-558</sup> , <i>yopP</i> <sub>23</sub> , <i>yopM</i> <sub>23</sub>	see Example 2 of the present specification
	Suicide Vectors and mutators	
pKNG101	<i>ori</i> R6K <i>sac</i> BR <sup>+</sup> <i>on</i> TRK2 <i>str</i> AB <sup>+</sup>	K. Kaniga et al. (1991) Gene 109: 137-141.
pMRS101	<i>ori</i> R6K <i>sac</i> BR <sup>+</sup> <i>on</i> TRK2 <i>str</i> AB <sup>+</sup> <i>ori</i> ColE1 <i>bla</i> <sup>+</sup>	M.R. Sarker and G.R. Cornelis (1997) Mol. Microbiol. 23: 409-411.
pAB31	pMRS101 <i>yopH</i> Δ <sup>1-352</sup> <sup>+</sup>	S.D. Mills et al. (1997) Proc. Natl. Acad. Sci. USA 94: 12638-12643.
pAB34	pMRS101 <i>yopO</i> Δ <sup>65-558</sup> <sup>+</sup>	S.D. Mills et al. (1997)
pAB38	pMRS101 <i>yopM</i> <sub>23</sub> <sup>+</sup>	S.D. Mills et al. (1997)
pMSK7	pMRS101 <i>yopP</i> <sub>23</sub> <sup>+</sup>	S.D. Mills et al. (1997)
pPW52	pKNG101 <i>yopE</i> <sub>21</sub> <sup>+</sup>	P. Wattiau and G.R. Cornelis (1993) Mol. Microbiol. 8: 123-131.

Generation of recombinant *Yersinia* containing YopE<sub>130</sub>-MAGE-A1

**[0100]** The sequence encoding protein MAGE-A1 was inserted in frame with a sequence encoding a truncated YopE, YopE<sub>130</sub>, containing the first 130 amino acids of YopE. Such a plasmid is graphically depicted in **Figure 1**.

**[0101]** The open reading frame of MAGE-A1 was amplified by PCR using a MAGE-A1 cDNA cloned in pcDNA1/Amp (Invitrogen, Carlsbad, California) as template. The upstream primer, AACTGCAGATGTCTCTTGAGCAGAGGAGTC

(SEQ ID NO: 33), consisted of the first nucleotides of the open reading frame of MAGE-A1 preceded by a PstI site. The downstream primer, AAAGTGCAGTCAGACTCCCTCTTCCTCCTC (SEQ ID NO: 34), consisted of nucleotides complementary to the last nucleotides of the open reading frame of MAGE-A1 followed by a PstI site. The PCR product was digested with PstI and inserted in frame with the truncated YopE at the PstI site of vector pMS111 (see, Sory et al. (1994) Molecular Microbiology 14: 583-594), to yield plasmid YopE<sub>130</sub>-MAGE-A1 or pMS111-MAGE-A1.

[0102] pMS111-MAGE-A1 (YopE<sub>130</sub>-MAGE-A1) was electroporated in bacteria strain DH5 F'IQ. DNA was extracted from some clones and the DNA of a positive recombinant clone was electroporated in bacteria strain SM10. After mobilization of pMS111 from SM10 in *Yersinia* MRS40 (pABL403), recombinant clones were then selected on agar-containing medium, supplemented with nalidixic acid, sodium-arsenite and chloramphenicol. MRS40 is an isogenic derivative of E40 sensitive to ampicillin (see, Sory et al. (1995) Proc. Natl. Acad. Sci. USA 92: 11998-12002).

#### Generation of recombinant *Yersinia* containing YopE<sub>130</sub>-MAGE-A4

[0103] The sequence encoding protein MAGE-A4 was linked in frame to a sequence encoding a truncated YopE, YopE (1-130), containing the first 130 amino acids of YopE. The open reading frame of MAGE-A4 was amplified by PCR using a MAGE-A4 cDNA cloned in pcDNAI/Amp (Invitrogen) as template. The upstream primer, AAAAAGTGCAGATGTCTTCTGAGCAGAAGAGT (SEQ ID NO: 35), consisted of the first nucleotides of the open reading frame of MAGE-A4 preceded by a PstI site. The downstream primer, AAAAATCGATTCAGACTCCCTCTTCCTC (SEQ ID NO: 36), consisted of nucleotides complementary to the last nucleotides of the open reading frame of MAGE-A4 followed by a ClaI site. The PCR was performed for 30 cycles (1 min at 94°C, 2 min at 55°C and 2 min at 72°C). The PCR product was digested with PstI and ClaI and inserted in frame with the truncated YopE at the PstI-ClaI sites of vector pMS621. Plasmid pMS621-MAGE-A4 was transformed into bacteria strain DH5αF'IQ by electroporation. Positive clones were detected by PCR on bacterial colonies and the DNA of a positive recombinant clone was extracted and transformed into bacteria strain SM10 by electroporation. After mobilization of pMS621-MAGE-A4 from SM10 into polymutant *Yersinia* MRS40 (pABL403), recombinant clones were then selected on agar-containing medium, supplemented with nalidixic acid, sodium m-arsenite and chloramphenicol.

#### Generation of recombinant *Yersinia*-MAGE-A3

*Yersinia*-MAGE-A3(aa147-314)

[0104] The sequences encoding the truncated MAGE-A3 was amplified by PCR using a MAGE-A3 cDNA cloned in pcDNAI/Amp as template. The upstream primer PVB157 was 5'-AA **CTGCAG** TTTCTGTGATCTTCAGCAAAGC-3' (SEQ ID NO: 50), consisting of nucleotides 439-461 of the open reading frame of MAGE-A3 (start codon ATG is 1-3), preceded by a PstI site (in bold) and 2 A's. The downstream primer PVB139, 5'-CC **ATCGAT** TCACTCTTCCCCCTCTCTCAA-3' (SEQ ID NO: 51), consisting of nucleotides complementary to the last nucleotides of the open reading frame of MAGE-A3 preceded by a ClaI site (in bold) and 2 C's. PCR was performed for 30 cycles (1 min at 94°C, 2 min at 62°C and 2 min at 72°C). The PCR products were treated as described for MAGE-A4 hereinabove.

Construction of *Yersinia*-MAGE-A3(aa1-199)

[0105] To obtain the sequence encoding the first 199 amino-acids of the MAGE-A3 protein, the primers were designed as follows: upstream primer PVB172, 5'-ACCAGAGTCATC **CTGCAG** ATGCCTCTTGAG -3' (SEQ ID NO: 52), consisting of the nucleotides overlapping the start codon (underlined) of the open reading frame of MAGE-A3 preceded by a PstI site (in bold). The downstream primer PVB 173, 5'-GCCTGCCTTGGG **ATCGAT** TCACATGATCTGATT-3' (SEQ ID NO: 53), consisting of nucleotides complementary to the nucleotides 577-600 of the open reading frame of MAGE-A3 and containing a ClaI site (in bold). PCR was performed for 30 cycles (1 min at 94°C, 2 min at 65°C and 2 min at 72°C). The PCR products were treated as described hereinabove for MAGE-A4.

#### Targeting EBV-Transformed B Cells with Recombinant *Yersinia*

[0106] Infection of EBV-transformed B cells with *Yersinia* MRS40 (pABL403) containing pMS111-MAGE-A1 was carried out as follows. Infection of EBV-transformed B cells with other recombinant *Yersinia* was carried out following essentially the same procedure.

[0107] One colony of *Yersinia* MRS40 (pABL403) containing pMS111-MAGE-A1 was then grown overnight at 28°C in LB medium supplemented with nalidixic acid (35 µg/ml), sodium m-arsenite (1 mM) and chloramphenicol (12 µg/ml). The overnight culture was diluted in fresh medium in order to obtain an OD (optical density) of 0.2 at 600nm after amplifying the fresh culture at 28°C for approximately 2 hours. The bacteria were washed in 0.9% NaCl and resuspended

at  $10^8$  bacteria per ml in 0.9% NaCl assuming that a culture giving an  $OD_{600}$  equal to 1 contains  $5 \times 10^8$  bacteria per ml. Irradiated EBV-B cells (100Gy) were resuspended at  $10^6$  in 3.8 ml of RPMI without antibiotics, supplemented with 10% FCS and AAG (L-Arginine (116 mg/ml), L-Asparagine (36 mg/ml) and L-Glutamine (216 mg/ml)). Then 200  $\mu$ l of the bacterial suspension was added. Two hours after infection, gentamicin (30  $\mu$ g/ml) was added for the next two hours, and the cells were finally washed three times before being used as stimulator cells.

[0108] As a negative control, the same cells were also infected with *Yersinia* MRS40 (pABL403) containing pMS621, a plasmid which encodes only the truncated YopE, i.e., YopE<sub>130</sub>.

[0109] EBV-B Cells infected with the recombinant *Yersinia*-MAGE-A1 were recognized by MZ2-CTL 82/30. MZ2-CTL 82/30 are specific for the MAGE-A1 peptide EADPTGHSY (SEQ ID NO: 1) which is presented by HLA-A1 (U.S. Patent No. 5,342,774). 5000 MZ2-CTL 82/30 cells were added in each microwell containing the *Yersinia* in a final volume of 100  $\mu$ l of Iscove's complete medium (culture medium was supplemented with 10% human serum, L-arginine (116 mg/ml), L-asparagine (36 mg/ml), L-glutamine (216 mg/ml), streptomycin (0.1 mg/ml), penicillin (200 U/ml), IL-2 (25 U/ml) and gentamicin (15  $\mu$ g/ml). After overnight incubation, the presence of IFN-gamma (that is produced by CTL upon activation) in the supernatant of the coculture was tested in a standard ELISA assay (Biosource, Fleurus, Belgium). **Figure 2A** graphically depicts such a procedure.

[0110] As indicated in **Figure 2B**, the HLA-A1<sup>+</sup> B cells infected with *Yersinia* encoding YopE<sub>130</sub>-MAGE-A1 were recognized by the CTL 82/30, while the same cells infected with the control plasmid YopE<sub>130</sub> were not. The optimal concentration of bacteria is around 1,000,000 per microwell.

## EXAMPLE 2

### GENERATION OF RECOMBINANT VACCINIA WR VIRUSES

[0111] Parental WR strain of Vaccinia (vP1170) contained the parent vector pKILGPT of 2826 bp (Virogenetics, Troy, New York). A sequence coding for MAGE-A1, placed after the Vaccinia Virus H6 promoter, was cloned into the pKILGPT vector, creating donor plasmid MAW035. A similar MAGE-A4 donor plasmid vector was constructed by replacing the MAGE-A1 cDNA with the MAGE-A4 cDNA. The MAGE-A3 cDNA was digested with Pst1 and Xba1, blunt ended, the insert was gel purified and ligated into the Sma1 site of the PsC11 vector. For the PsC11 vector, see Chakrabati et al. (1985) Mol. Cell Biol. 5: 34-3-3409.

[0112] The donor plasmids was transfected into CEF cells containing the genomic DNA of vaccinia strain WR, yielding recombinant vaccinia viruses WR-MAGE-A1, WR-MAGE-A4 and WR-MAGE-A3, respectively, by way of *in vivo* recombination and selected with BrdU and X-gal. The procedure can be found in, e.g., Perkins et al. (1989) J. Virol. 63: 3829-3936.

## EXAMPLE 3

### GENERATION OF RECOMBINANT ALVAC-MAGE-A1 VIRUSES

[0113] A MAGE-A1 coding sequence, placed after the Vaccinia Virus H6 promoter, was cloned into the pUC8-based vector to generate donor plasmid MAW036.

[0114] Recombinant ALVAC-MAGE-A1 virus was generated by using the donor plasmid MAW036 and following well known procedures, e.g., as described in Current Protocols in Molecular Cloning (Ausubel et al., John Wiley & Sons, New York) and Ferrari et al. (Blood 90: 2406-2416, 1997).

[0115] Recombinant canarypox virus ALVAC-MAGE-A3 split (also referred to herein as "ALVAC-MAGE-A3" for simplicity) expressed two truncated overlapping fragments of MAGE-A3, one fragment spanning amino acids 1-196 and the other fragment spanning amino acids 147-199. In the recombinant virus, each fragment was contained in a separate expression cassette, each under the control of the vaccinia virus H6 promoter, and both cassettes were inserted at the C3 site in the ALVAC genome.

[0116] The vCP1563 recombinant was generated as follows. The MAGE-A3 (1-196) DNA fragment was generated and linked to the vaccinia H6 promoter by standard PCR procedures with plasmid pTZ18R (containing full length MAGE-A3 cDNA) as template. The MAGE-A3 (147-199) DNA fragment was generated and linked to the H6 promoter in the same way. These two fragments were then subcloned into a plasmid such that the cassettes were flanked by ALVAC DNA from the C3 insertion site. The organization of these elements in the plasmid was as follows: ALVAC C3 left flanking arm, MAGE-A3 (147-299)/H6, MAGE-A3 (1-196)/H6, ALVAC C3 right flanking arm. This ALVAC C3 site donor plasmid containing the MAGE-A3 (1-196) and (147-299) fragment expression cassettes was designated pC3MAGE3 split.

[0117] The ALVAC-MAGE-A3 recombinant was generated by *in vivo* recombination between the pC3MAGE3 split donor plasmid and ALVAC genomic DNA following standard procedures. Recombinant virus was selected by hybridization with MAGE-3-specific DNA probes and plaque was purified. The resulting ALVAC-MAGE-A3 recombinant was given

the laboratory designation vCP1563. Expression analysis with MAGE-3-specific antisera confirmed the expression of MAGE-A3 (1-196) and (147-299) polypeptides in cells infected with ALVAC-MAGE-A3 (vCP1563).

#### EXAMPLE 4

##### GENERATION OF RECOMBINANT ADENOVIRUSES

[0118] For the construction of the recombinant adenovirus, the plasmid pAd-CMVlcpA-MAGE-A4 (containing the MAGE-A4 cDNA under the control of the CMV promoter) was obtained by inserting into the NotI site of vector pAd-CMVlcpA (provided by Celia GARCIA and Thierry RAGOT, URA CNRS 1301), the MAGE-A4 complete cDNA.

[0119] The recombinant adenovirus Ad-MAGE-A4 was generated by *in vivo* homologous recombination in cell line 293 between pAd-CMVlcpA-MAGE-A4 and Ad-βgal genomic DNA. Briefly, 293 cells were cotransfected with 5 μg of plasmid pAd-CMVlcpA-MAGE-A4 linearized with XmnI and 5 μg of the large ClaI fragment of Adeno-βgal DNA (Stratford-Perricaudet et al. (1992), J. Clin. Invest., 90: 626-630 and Patent FR 9603207). The recombinant adenovirus was plaque purified and the presence of the transgene was assessed by restriction analysis of the adenoviral DNA. Recombinant adenoviruses were propagated in 293 cells and purified by double cesium chloride density centrifugation. The viral stocks were stored in aliquots with 10% glycerol in liquid nitrogen and titered by plaque assay using 293 cells.

[0120] Recombinant adenovirus Ad-MAGE-A3 was generated according to essentially the same procedure described above, but MAGE-A3 cDNA was derived from a λgt10 recombinant clone.

#### EXAMPLE 5

##### RECOMBINANT RETROVIRUS AND INFECTION OF CELL LINES

[0121] The M1-CSM retroviral vector encodes the full length MAGE-A1 protein, under the control of the LTR, and the truncated form of the human low affinity nerve growth factor receptor (ΔLNGFr) driven by the SV40 promoter (Mavilio F. et al., Blood 83: 1988-1997, 1994). EBV-B cells or PHA-activated T cells were transduced by coculture with irradiated packaging cell lines producing the M1-CSM vector in the presence of polybrene (8 μg/ml). After 72 hours, lymphocytes were harvested and seeded in fresh medium. The percentage of infected cells was evaluated 48 hours later by flow cytometry for LNGFr expression with the mAb 20.4 (ATCC, Rockville, MD, USA). The LNGFr positive cells were purified by magnetic cell sorting using Rat anti-mouse IgG1-coated beads (Dynabeads M-450, DYNAL A.S. N012 Oslo, Norway).

#### EXAMPLE 6

##### MATERIALS AND METHODS

###### Cell lines and Media

[0122] The Epstein Barr Virus (EBV) immortalized B cells (hereafter referred as to EBV-B cells) were obtained following the standard protocol. EBV-B cells and the melanoma cell lines were cultured in Iscove's modified Dulbecco medium (IMDM) (GIBCO BRL, Baithsburg, MD, USA) supplemented with 10% fetal calf serum (FCS) (GIBCO BRL), 0.24 mM L-asparagine, 0.55 mM L-arginine, 1.5 mM L-glutamine (AAG), 100 U/ml penicillin and 100 μg/ml streptomycin. HeLa and COS-7 cells were maintained in H16 medium (GIBCO BRL) supplemented with 10% FCS.

###### Cytokines

[0123] Human recombinant IL-2 was purchased from CHIRON BV (Amsterdam, Netherlands) or EURO CETUS (Amsterdam, Netherlands), or provided by BIOGEN (Geneva, Switzerland). Human recombinant IL-7 was purchased from GENZYME (Cambridge, MA). Human recombinant GM-CSF was purchased from SANDOZ (Leucomax, Sandoz Pharma, Basel, Switzerland) or SCHERING PLOUGH (Brinny, Ireland). Human recombinant IL-4, IL-6 and IL-12 were produced by the present inventors.

###### Processing of human blood

[0124] Peripheral blood was obtained from the local blood bank (non cancer patients, namely, hemochromatosis patients) as standard buffy coat preparations. Peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on Lymphoprep (NYCOMED PHARMA, Oslo, Norway). In order to minimize contamination of PBMC by platelets, the preparation was first centrifuged for 20 min at 1000 rpm at room temperature. After removal of the top 20-25 ml containing



most of the platelets, the tubes were centrifuged for 20 min at 1500 rpm at room temperature. PBMC were depleted of T cells by rosetting with sheep erythrocytes (BIO MÉRIEUX, Marcy-l'Etoile, France) treated with 2-aminoethyl-isothiuronium (SIGMA, St. Louis, MO, USA). Rosetted T cells were treated with  $\text{NH}_4\text{Cl}$  (160 mM) to lyse the sheep erythrocytes and washed. The  $\text{CD8}^+$  T lymphocytes were isolated by positive selection using an anti-CD8 monoclonal antibody coupled to magnetic microbeads (MILTENYI BIOTECH, Germany) and by sorting through a magnet. The  $\text{CD8}^+$  T lymphocytes were frozen, and thawed the day before the start of the primary culture and cultured overnight in Iscove's medium containing L-asparagine (0.24 mM), L-arginine (0.55 mM), L-glutamine (1.5 mM), 10% human serum (hereafter referred to as complete Iscove's medium) and supplemented with 2.5 U/ml IL-2.

**[0125]** The lymphocyte-depleted PBMC were frozen or used immediately for dendritic cell cultures. Cells were left to adhere for 1-2 hrs at  $37^\circ\text{C}$  in culture flasks (Falcon, BECTON DICKINSON LABWARE, Franklin Lakes, USA) at a density of  $2 \times 10^6$  cells/ml in RPMI 1640 medium (GIBCO BRL) supplemented with L-asparagine (0.24 mM), L-arginine (0.55 mM), L-glutamine (1.5 mM) and 10% fetal calf serum (hereinafter referred to as complete RPMI medium). Non-adherent cells were discarded and adherent cells were cultured in the presence of IL-4 (100 U/ml) and GM-CSF (100 ng/ml) in complete RPMI medium. For experiments in Examples 7 and 8, cultures were fed on day 2 and day 4 by removing 1/3 of the volume of the medium and adding fresh medium with IL-4 (100 U/ml) and GM-CSF (100 ng/ml); and on day 6 or 7, the non-adherent cell population was used as a source of enriched dendritic cells. For experiments in Example 9, cultures were fed on day 2 by removing 1/3 of the volume of the medium and adding fresh medium with IL-4 (100 U/ml) and GM-CSF (100 ng/ml) and were frozen on day 4; and on the day before each stimulation, dendritic cells were thawed and grown overnight in complete medium supplemented with 100 U/ml IL-4 and 100 ng/ml GM-CSF. For experiments in Examples 10-11, cultures were fed on day 2 and 4 by removing 1/2 or 1/3 of the volume of the medium and adding fresh medium with IL-4 (100 U/ml) and GM-CSF (100 ng/ml); and on day 5 or day 7, the non-adherent cell population was used as a source of enriched dendritic cells.

#### Interferon $\gamma$ production assay.

**[0126]** 5000 target cells were cultured overnight with 2000 CTL in 100  $\mu\text{l}$  per well complete Iscove's medium supplemented with 25 U/ml IL-2 in 96 well round bottom plates. The production of interferon  $\gamma$  (IFN- $\gamma$ ) was measured in 50  $\mu\text{l}$  supernatant by ELISA (Biosource).

#### cDNAs encoding HLA-class I molecules

**[0127]** The HLA-A\*0201 coding sequence was obtained from a cDNA library of cell line BB49, cloned into expression vector pcDNA1/Amp (INVITROGEN). The HLA-A3 coding sequence was isolated from a cDNA library of cell line LB33 cloned into expression vector pcDNA3 (INVITROGEN). The HLA-B\*4402 coding sequence was isolated by RT-PCR from cell line LB33 and cloned in expression vector pcDNA1/Amp. The HLA-B\*40012 (B60) coding sequence was derived by RT-PCR from cell line HA7-RCC and cloned in expression vector pcDNA3. The HLA-Cw3 coding sequence was cloned in expression vector pCR3. The HLA-Cw5 was isolated from cell line LB373 by RT-PCR and cloned into pcDNA3. The HLA-B\*0801, B\*4002 (B61), Cw\*02022, and Cw\*0701 coding sequences were amplified by RT-PCR using RNA of LB 1118-EBV-B cells as the template. The HLA-B\*5301 coding sequence was amplified by RT-PCR using RNA of EBV-B cells of patient LB 1118 as the template. The HLA-B7 and HLA-B40 segments were isolated as described in Examples 12 and 13. PCR products were cloned into expression vector pcDNA3. DNA was extracted from recombinant clones and sequenced partially on the sense and partially on the antisense strand by the dideoxy-chain termination method (Thermosequenase<sup>TM</sup> cycle sequencing kit, Amersham).

#### Peptides recognition assay

**[0128]** Peptides were synthesized on solid phase using F-moc for transient  $\text{NH}_2$ -terminal protection and were characterized using mass spectrometry. All peptides were >80% pure, as indicated by analytical HPLC. Lyophilized peptides were dissolved in DMSO and stored at  $-20^\circ\text{C}$ . Target cells were labeled with  $\text{Na}^{(51)\text{Cr}}\text{O}_4$ , washed, and incubated for 15 min in the presence of peptide. CTL clone was then added at an effector-to-target ratio of 5:1 to 10:1. Chromium release was measured after incubation at  $37^\circ\text{C}$  for 4 hours.

**Example 7****A MAGE-A1 DERIVED PEPTIDE PRESENTED BY HLA-Cw3 MOLECULES TO CYTOLYTIC T LYMPHOCYTES****Isolation of MAGE-A1 specific CTL clone LB1137 462/F3.2**

**[0129]** Autologous dendritic cells from donor LB 1137 (HLA-A2 A3 B4402 B60 Cw3 Cw5) were infected with the ALVAC-MAGE-A1 at a multiplicity of infection of 30 in RPMI containing 10% FCS at 37°C under 5% CO<sub>2</sub>. After 2 hours, the infected dendritic cells were washed. For *in vitro* stimulation, 150,000 CD8<sup>+</sup> T lymphocytes and 30,000 infected dendritic cells were cocultured in microwells in 200 µl Iscove's medium containing L-asparagine (0.24 mM), L-arginine (0.55 mM), L-glutamine (1.5 mM), 10% human serum (hereafter referred to as complete Iscove's medium) and supplemented with IL-6 (1000 U/ml) and IL-12 (10 ng/ml). The CD8<sup>+</sup> lymphocytes were weekly restimulated with autologous dendritic cells freshly infected with the ALVAC-MAGE-A1 and grown in complete Iscove's medium supplemented with IL-2 (10 U/ml) and IL-7 (5 ng/ml).

**[0130]** After several rounds of stimulation, an aliquot of each microculture was tested for specific lysis of autologous target cells. Autologous EBV-B cells were infected for two hours with either the parental vaccinia WR (batch LVAR) or the WR-MAGE-A1 construct (vP 1267), using a multiplicity of infection of 20, and labeled with Na(<sup>51</sup>Cr)O<sub>4</sub>. Afterwards, EBV-B cells (target cells) were washed, and added to the responder cells at an effector to target ratio of approximately 40:1. Unlabeled K562 cells were also added (5 x 10<sup>4</sup> per V-bottomed microwell) to block natural killer activity. Chromium release was measured after incubation at 37°C for 4 hours. The individual microcultures were tested in duplicate on each target.

**[0131]** The positive microcultures were cloned by limiting dilution, using autologous EBV-B cells infected with recombinant *Yersinia* expressing the YopE<sub>130</sub>-MAGE-A1 protein as stimulating cells, and allogeneic EBV-B cells (LG2-EBV) as feeder cells. The cultures were restimulated similarly on day 7, and clones were maintained in culture by weekly restimulation with allogeneic EBV-B cells (LG2-EBV) in complete Iscove's medium supplemented with 0.5 µg/ml PHA-HA16 (Murex) and 50 U/ml of IL-2. At day 3 after restimulation, the clones were washed to remove the PHA-HA16 in the culture medium. The clones were tested for specific lysis of autologous EBV-B cells infected with the vaccinia-MAGE-A1 construct. Clone LB1137 462/F3.2 was found positive (**Figure 3a**) and used in subsequent experiments.

**The MAGE-A1 epitope is presented to CTL by HLA-Cw3 molecules**

**[0132]** As donor LB 1137 expresses a number of different HLA molecules as described supra, each HLA was tested to determine which one presented the antigen recognized by CTL LB1137 462/F3.2.

**[0133]** COS cells were transfected with plasmids encoding one of the six HLA-class I molecules together with the cDNA of MAGE-A1. In brief, 1.5 x 10<sup>4</sup> COS cells distributed in microwells were cotransfected with 50 ng of plasmid pcDNA1 containing the MAGE-A1 cDNA and 50 ng of plasmid pcDNA3 containing the cDNA coding for one of the six HLA-class I molecules that were expressed by donor LB1137, using 1 µl of Lipofectamine reagent (Gibco BRL). The COS cells were incubated 5 hours at 37°C and 8% CO<sub>2</sub> in the transfection mixture and 200 µl of culture medium was added. After overnight culture, transfectants were tested for their ability to stimulate the production of IFN-γ by clone LB1137 462/F3.2. Briefly, 1500 CTLs were added to each microwell containing transfected cells, in a final volume of 100 µl of Iscove's complete medium containing 25 U/ml of IL-2. After 24 hours, 50 µl supernatant was tested for its IFN-γ content in a WEHI bioassay which measured the cytotoxic effect of IFN-γ on cells of WEHI-164 clone 13 in a MTT colorimetric assay. Only those cells transfected with both HLA-Cw3 and MAGE-A1 stimulated CTL clone LB1137 462/F3.2 to produce IFN-γ (**Figure 3b**). COS cells transfected with MAGE-A1 or HLA-Cw3 alone did not stimulate the CTL clone.

**Antigenic peptides and CTL assay.**

**[0134]** In order to identify the MAGE-A1 peptide recognized by clone LB1137 462/F3.2, peptides (16 amino-acids) corresponding to parts of the MAGE-A1 protein were synthesized, loaded on the autologous EBV-B cells and tested for recognition. Peptides were synthesized on solid phase using F-moc for transient NH<sub>2</sub>-terminal protection. Lyophilized peptides were dissolved at 20 mg/ml in DMSO, diluted at 2 mg/ml in 10 mM acetic acid and stored at -20°C.

**[0135]** Peptides were tested in chromium release assays in which 1000 <sup>51</sup>Cr-labeled target cells were incubated with 10 µg/ml of peptide in 96-well microplates (100 µl/well) for 20 min at room temperature, prior to adding 100 µl medium containing 10,000 CTL. The assay was terminated after 4 hours of incubation at 37°C and 8% CO<sub>2</sub>.

**[0136]** Autologous EBV-B cells incubated with peptide DGREHSAYGEPRKLLT (MAGE-A1<sub>225-240</sub>) (SEQ ID NO: 37) were recognized by CTL LB1137 462/F3.2 (**Figure 3c**). This long peptide contained a 9-amino-acid peptide SAYGEPRKL (MAGE-A1<sub>230-238</sub>) (SEQ ID NO: 2) which contained adequate anchor residues for HLA-Cw3: a Y in position 3 and a L at the C-terminus. DGREHSAYGEPRKLLT (SEQ ID NO: 37) was screened for prediction of an HLA-Cw3 binding peptide

with the software available at "[http://bimas.dcrt.nih.gov/molbio/hla\\_bind/index.html](http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html)". Peptide SAYGEPRKL (MAGE-A1<sub>230-238</sub>) (SEQ ID NO: 2) had the highest score for binding to HLA-Cw3. It was recognized by CTLLB1137 462/F3.2 in a cytotoxicity assay at an effector to target ratio of 10:1 (Figure 3c).

#### Recognition by CTL clone LB1137 462/F3.2 of HLA-Cw3 positive tumor cells expressing MAGE-A1

[0137] The activation of CTL LB1137 462/F3.2 by tumor cell lines that express HLA-Cw3 and MAGE-A1 was tested in an IFN- $\gamma$  production assay. CTL clone LB1137 462/F3.2 recognized the HLA-Cw3 positive tumor cell line LB17-MEL which expresses MAGE-A1 (Figure 3d). The melanoma cell line Mi 665/2 E+ clone 2, that was transfected with a genomic fragment containing the open reading frame of MAGE-A1 (as described in U.S. Patent NO. 5,342,774), was also recognized by clone LB1137 462/F3.2, whereas the parental cell line Mi 665/2 was not recognized.

#### Example 8

#### A MAGE-A1 DERIVED PEPTIDE PRESENTED BY HLA-B5301 MOLECULES TO CYTOLYTIC T LYMPHOCYTES

##### Isolation of MAGE-A1 specific CTL clone LB1801 456/H7.11

[0138] Autologous dendritic cells from donor LB1801 (HLA-A201, A28, B4401, B5301, Cw04, Cw0501) were infected with the ALVAC-MAGE-A1 construct at a multiplicity of infection of 30 in RPMI containing 10% FCS at 37°C under 5% CO<sub>2</sub>. After 2 hours, the infected dendritic cells were washed twice. For *in vitro* stimulation, 150,000 CD8+ lymphocytes and 30,000 infected dendritic cells were cocultured in round bottomed microwells in 200 microliters Iscove's medium containing L-asparagine (0.24 mM), L-arginine (0.55 mM), L-glutamine (1.5 mM), 10% human serum (hereafter referred as complete Iscove's medium) and supplemented with IL-6 (1000 U/ml) and IL12 (10 ng/ml). The CD8+ lymphocytes were weekly restimulated with autologous dendritic cells freshly infected with the ALVAC-MAGE-A1 construct and grown in complete Iscove's medium supplemented with IL-2 (10 U/ml) and IL-7 (5 ng/ml).

[0139] Autologous EBV-B cells were infected for 2 hours with either the parental vaccinia WR (vP1170) or the recombinant vaccinia WR-MAGE-A1 (vP1188) using a multiplicity of infection of 20, and labeled with Na(<sup>51</sup>Cr)O<sub>4</sub>. Target cells were washed, and added to the responder cells at an effector to target ratio of approximately 40:1. Unlabeled K562 were also added (5 x 10<sup>4</sup> per V-bottomed microwell) to block natural killer activity. Chromium release was measured after incubation at 37°C for 4 hours. The individual microcultures were tested in duplicate on each target.

[0140] The microcultures containing cells that specifically lysed autologous EBV-B cells infected with the vaccinia-MAGE-A1 construct were cloned by limiting dilution using autologous EBV-B cells previously infected with the *Yersinia* expressing YopE<sub>1-130</sub>-MAGE-A1 as stimulating cells, and allogeneic EBV-B cells (LG2-EBV) as feeder cells. CTL clones were maintained in culture by weekly restimulation in complete Iscove's medium supplemented with 50 U/ml of IL2. The clones were tested for specific lysis of autologous EBV-B cells infected with the vaccinia-MAGE-A1 construct. Clone LB1801 456/H7.11 was found positive (Figure 4a) and used in the following experiments. The CTL was restimulated weekly with LG2-EBV as feeder cells and alternately, purified phytohaemagglutinin (PHA-HA16; MUREX) (0.5 mg/ml) or autologous EBV-B cells previously infected with the *Yersinia*-YopE<sub>1-130</sub>-MAGE-A1.

##### Antigenic peptides and CTL assay

[0141] In order to identify the MAGE-A1 peptide recognized by clone LB1801 456/H7.11, peptides (16 amino-acids) corresponding to parts of the MAGE-A1 protein were synthesized, loaded on the autologous EBV-B cells and tested for recognition. Peptides were synthesized on solid phase using F-moc for transient NH<sub>2</sub>-terminal protection. Lyophilized peptides were dissolved at 20 mg/ml in DMSO, diluted at 2 mg/ml in 10 mM acetic acid and stored at -20°C. Peptides were tested in chromium release assay where 1000 <sup>51</sup>Cr-labeled target cells were incubated for 15 min at room temperature in V-bottomed microplates with 5  $\mu$ g/ml of peptide, before adding an equal volume containing 5,000 CTLs. The assay was terminated after 4 hours of incubation at 37°C and 8% CO<sub>2</sub>. Peptides QVPDSDPARYEFLWGP (MAGE-A1<sub>253-268</sub>) (SEQ ID NO: 38) and SDPARYEFLWGPRALA (MAGE-A1<sub>257-272</sub>) (SEQ ID NO: 39) scored positive.

##### Identification of the HLA presenting molecule

[0142] To know which HLA molecule presented both 16-mers peptides to CTL clone LB1801 456/H7.11, peptides were tested in a chromium release assay using, as target cells, EBV-B cells from different donors that shared HLA molecules with donor LB1801. Clone LB1801 456/H7.11 were able to recognize the peptide only when presented by autologous cells (Table 4). Because, no EBV-B cells expressing the HLA-B5301 molecule was tested, the cDNA coding for HLA-B5301 of donor LB1801 was isolated.

**[0143]** The HLA-B5301 coding sequence was amplified by RT-PCR using RNA of LB1801-EBV-transformed B cells as template. The PCR products were cloned into expression vector pcDNA3 (Invitrogen BV, the Netherlands). DNA was extracted from recombinant clones and sequenced partially on the sense and partially on the antisense strand to check that it was a sequence encoding HLA-B5301. The sequence for HLA-B5301 is described by Mason and Pasham (1998), Tissue Antigens 51: 417-466.

**[0144]** COS-7 cells were transfected with plasmids encoding HLA-B5301 molecule together with MAGE-A1 cDNA. In brief,  $1.5 \times 10^4$  COS-7 cells distributed in microwells were cotransfected with 100 ng of plasmid pcDNA1 containing the MAGE-A1 cDNA, 100 ng of plasmid pcDNA3 containing the cDNA coding for HLA-B5301 molecule of donor LB 1801, and one microliter of lipofectamine (Gibco BRL). The COS-7 cells were incubated 24 hours at 37°C and 8% CO<sub>2</sub>. These transfectants were then tested for their ability to stimulate the production of TNF by clone LB1801 456/H7.11. Briefly, 1,500 CTLs were added to the microwells containing

**Table 4**

Target Cells	HLA Typing			% of Lysis	
				No Peptide	SDPARYEFLWGPRALA
LB1801	A2 A28	B4402 B53	CwD4 Cw0501	5	41
LB1118	A2 A3	B8 B61	Cw2 Cw7	19	15
LB33	A24 A28	B13 B4402	Cw6 Cw7	22	18
LB1158	A2 A3	B35 B51	Cw1 Cw4	6	4
LB1137	A2 A3	B4402 B60	Cw3 Cw5	5	3
LG2	A24 A32	B3503 B4403	Cw4	1	4
LB1819	A2	B44 B57	Cw5 Cw7	0	4
LB1161	A3 A26	B39 B4402		1	8
LB1213	A24	B18 B35	Cw4 Cw7	0	4
Table 4: Lysis by CTL LB1801 456/H7.11 of various EBV-B cells (target cells) pulsed with MAGE-A1 peptide.					
EBV-B cells were 51Cr labeled and incubated with CTL at an effector to target cell ratio of 5/1 in the presence (or not) of 5 microgrammes of peptide SDPARYEFLWGPRALA (SEQ ID NO: 39). Chromium release was measured after 4 hours.					

the transfectants, in a total volume of 100 ml of Iscove's complete medium containing 25 U/ml of IL-2. After 24 hours, the supernatant was collected and its TNF content was determined by testing its cytotoxic effect on cells of WEHI-164 clone 13 in a standard MTT colorimetric assay. The cells transfected with both HLA-B53 and MAGE-A1 stimulated CTL clone LB1801 456/H7.11 to produce TNF (**Figure 4b**). COS-7 cells transfected with MAGE-A1 or HLA-B53 alone did not stimulate the CTL clone.

#### Identification of the antigenic peptide

**[0145]** To identify the sequence of the shortest synthetic peptide recognized by clone LB1801 456/H7.11, we compared the lysis by the CTL of autologous EBV-B cells, loaded with the MAGE-A1 peptide SDPARYEFLWGPRALA (MAGE-A1 257-272) (SEQ ID NO: 39) or the MAGE-A4 peptide GSNPARYEFLWGPRAL (MAGE-A4 264-279) (SEQ ID NO: 40), in a chromium release at an effector target ratio of 10 and a final concentration of peptide of 5 µg/ml. The MAGE-A1 peptide, but not the MAGE-A4 peptide, was recognized. The 10-mer peptide SDPARYEFLW (SEQ ID NO: 41) and the 9-mer peptide DPARYEFLW (SEQ ID NO: 42) were then synthesized and tested in a cytotoxic assay at an effector to target ratio of 5. Both peptides were recognized. The shorter peptide was then tested at different concentration at an effector to target ratio of 10 (**Figure 4c**). Half-maximal lysis was obtained at between 10 and 100 ng/ml.

## Example 9

### A MAGE-A4 DERIVED PEPTIDE PRESENTED BY HLA-A2 MOLECULES TO CYTOLYTIC T LYMPHOCYTES

#### Isolation of MAGE-A4 specific CTL clone LB1137 H4.13

[0146] Autologous dendritic cells from donor LB 1137 (HLA-A2, -A3, -B4402, -B60, -Cw3, -Cw5) were infected with the Ad-MAGE-A4 construct at a multiplicity of infection of 200 in RPMI containing 10% FCS at 37°C under 5% CO<sub>2</sub>. After 2 hours, the infected dendritic cells were washed. For *in vitro* stimulation, 150,000 CD8<sup>+</sup> T lymphocytes and 30,000 infected dendritic cells were cocultured in microwells in 200 µl Iscove's medium containing L-asparagine (0.24 mM), L-arginine (0.55 mM), L-glutamine (1.5 mM), 10% human serum (hereafter referred to as complete Iscove's medium) and supplemented with IL-6 (1000 U/ml) and IL-12 (10 ng/ml). The CD8<sup>+</sup> lymphocytes were weekly restimulated with autologous dendritic cells freshly infected with the Ad-MAGE-A4 construct and grown in complete Iscove's medium supplemented with IL-2 (10 U/ml) and IL-7 (5 ng/ml). These cells were tested as responder cells in the following assay.

[0147] Autologous EBV-B cells were infected for 2 hours with either the parental vaccinia WR parent (batch vP1170 or batch L VAR) or the recombinant vaccinia WR-MAGE-A4 (batch vP1545) using a multiplicity of infection of 20, and labeled with Na(<sup>51</sup>Cr)O<sub>4</sub>. These target cells were washed, and added to the responder cells at an effector to target ratio of approximately 40:1. Unlabeled K562 cells were also added (5 x 10<sup>4</sup> per V-bottomed microwell) to block natural killer activity. Chromium release was measured after incubation at 37°C for 4 hours. The individual microcultures were tested in duplicate on each target.

[0148] The microcultures containing cells that specifically lysed autologous EBV-B cells infected with the vaccinia-MAGE-A4 construct were cloned by limiting dilution using, as stimulating cells, autologous EBV-B cells infected with the recombinant *Yersinia* expressing YopE<sub>1-130</sub>-MAGE-A4 (described above), and using allogeneic EBV-B cells (LG2-EBV) as feeder cells. Infection of EBV-B cells with *Yersinia* YopE<sub>1-130</sub>-MAGE-A4 was done as follows: one colony of *Yersinia* MRS40 (pABL403) containing pMS621-MAGE-A4 (YopE<sub>1-130</sub>-MAGE-A4) was grown overnight at 28°C in LB medium supplemented with nalidixic acid, sodium m-arsenite and chloramphenicol. From this culture, a fresh culture at an OD (600 nm) of 0.2 was then amplified at 28°C for approximately 2 hours. The bacteria were then washed in 0.9 % NaCl and resuspended at 10<sup>8</sup> bacteria per ml in 0.9 % NaCl. Irradiated EBV-B cells were infected at a multiplicity of infection of 20 in complete RPMI 1640 (culture media was supplemented with 10% FCS, and with L-arginine (116 mg/ml), L-asparagine (36 mg/ml), L-glutamine (216 mg/ml). Two hours after infection, gentamycin (30 µg/ml) was added for the next two hours, and the cells were finally washed 3 times. CTL clones were maintained in culture by weekly restimulation with either *Yersinia* YopE<sub>1-130</sub>-MAGE-A4 infected EBV-B cells, HLA-A2 melanoma cell line QUAR (LB1751-MEL) that expressed MAGE-A4, or PHA (0.5 µg/ml) in complete Iscove's medium supplemented with 50 U/ml of IL-2. The clones were tested for specific lysis of autologous EBV-B cells infected with the vaccinia-MAGE-A4 construct. Clone LB1137 H4.13 was found positive (Figure 5a) and used in the following experiments.

#### The MAGE-A4 epitope is presented to CTL by HLA-A2 molecules

[0149] The lysis by CTL clone LB1137 H4.13 of EBV-B cells infected with the vaccinia-MAGE-A4 construct was inhibited by addition of an anti-HLA-A2 monoclonal antibody but not by addition of an anti-HLA-A3 or an anti-HLA-B,C monoclonal antibody. This indicated that the MAGE-A4 epitope was presented by HLA-A2 molecules.

[0150] COS cells were transfected with plasmids encoding the HLA-A2 molecule together with the cDNA of MAGE-A4. In brief, 1.5 x 10<sup>4</sup> COS cells distributed in microwells were cotransfected with 50 ng of plasmid pcDNA1 containing the MAGE-A4 cDNA, 50 ng of plasmid pcDNA1/Amp containing the genomic DNA coding for the HLA-A2 molecule and 1 µl of DMRIEC (Gibco BRL). The COS cells were incubated 24 hours at 37°C and 8% CO<sub>2</sub>. These transfectants were then tested for their ability to stimulate the production of TNF by clone LB1137 H4.13. Briefly, 2000 CTL were added to the microwells containing the transfectants, in a total volume of 100 µl of Iscove's complete medium containing 25 U/ml of IL-2. After 24 hours, the supernatant was collected and its TNF content was determined by testing its cytotoxic effect on cells of WEHI-164 clone 13 in a standard MTT colorimetric assay. The cells transfected with both HLA-A2 and MAGE-A4 stimulated CTL clone LB1137 H4.13 to produce TNF (Figure 5b). COS cells transfected with MAGE-A4 or HLA-A2 alone did not stimulate the CTL clone.

#### Determination of the antigenic peptide

[0151] In order to identify the MAGE-A4 peptide recognized by clone LB1137 H4.13, PCR reactions were performed using the MAGE-A4 cDNA as template, an upstream primer (S) consisting of the first nucleotides of the open reading frame of MAGE-A4 and 8 downstream primers (AS1 to AS8) (Figure 6), separated from each other by approximately 100-120 bp in the open reading frame of MAGE-A4. The PCR was performed for 30 cycles (1 min at 94°C, 2 min at

63°C and 3 min at 72°C. This led to the amplification of 8 fragments of MAGE-A4 of different lengths (MAGE-A4(1) to MAGE-A4(8)), the longer one (MAGE-A4(1)) containing the entire open reading frame of MAGE-A4. PCR products were ligated into the pcDNA3.1/V5/His-TOPO vector and the recombinant vectors were transformed into *E. coli* cells (Topo TA cloning kit, Invitrogen). Colonies were analyzed by PCR and DNA of positive clones was extracted and used to transfect HeLa cells together with a plasmid encoding the HLA-A2 molecule. Briefly,  $2 \times 10^4$  HeLa cells distributed in microwells were cotransfected with 50 ng of plasmid pcDNA3.1/V5/His-TOPO containing the MAGE-4A fragment, 50 ng of plasmid pcDNA1/Amp containing the genomic DNA coding for the HLA-A2 molecule and 1  $\mu$ l of Lipofectamine (Gibco BRL). The HeLa cells were incubated 24 hours at 37°C and 8% CO<sub>2</sub>. These transfectants were then tested for their ability to stimulate the production of TNF by clone LB1137 H4.13 as described above. Transfection with inserts S-AS1 and S-AS2 were positive, transfections with the other constructs were negative. This led to the identification of a MAGE-4A fragment of 130 bp,

TGATGGGAGGGAGCACACTGTCTATGGGGAGCCCAGGAAACTGCTCACCCAAGATTG  
GGTGCAGGAAAACCTACCTGGAGTACCGGCAGGTACCCGGCAGTAATCCTGCGCGCTA  
TGAGTTCCTGTGGGGT (SEQ ID NO: 43),

encoding the epitope recognized by clone LB1137 H4.13.

**[0152]** The sequence of the putative fragment of the MAGE-A4 protein encoded by this region was screened for prediction of an HLA-A2 binding peptide with the software available at [http://bimas.dcrt.nih.gov/molbio/hla\\_bind/index.html](http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html). Peptide GYVDGREHTV (SEQ ID NO: 44) (MAGE-A4<sub>230-239</sub>) had the highest score. It was synthesized and tested in a cytotoxicity assay at an effector to target ratio of 10:1. Peptide GYVDGREHTV (MAGE-A4<sub>230-239</sub>) (SEQ ID NO: 44) was found to sensitize autologous target cells to lysis by clone LB1137 H4.13 (**Figure 5c**).

#### Recognition by CTL clone LB1137 H4.13 of HLA-A2 cells expressing MAGE-A4

**[0153]** As indicated in **Figure 5d**, CTL clone LB1137 H4.13 was able to lyse HLA-A2 melanoma cell line QUAR (LB1751-MEL) that expressed MAGE-A4.

#### EXAMPLE 10

##### A MAGE-A1 PEPTIDE PRESENTED BY HLA-Cw2 TO CTL CLONE LB1118 466/D3.31

##### Isolation Of CTL Clone LB1118 466/D3.31

**[0154]** Dendritic cells ( $3 \times 10^6$ /ml) from donor LB 1118 (HLA-A\*0201, A3, B\*0801, B\*4002, Cw\*02022, Cw\*0701) were infected with the ALVAC-MAGE-A1 at a multiplicity of infection of 30 in RPMI supplemented with AAG and 10% FCS at 37°C under 5% CO<sub>2</sub>. After 2 hours, the infected dendritic cells were washed. 150,000 autologous CD8<sup>+</sup> T lymphocytes and 30,000 infected dendritic cells were cocultured in microwells in 200  $\mu$ l complete Iscove's medium and supplemented with IL-6 (1000 U/ml) and IL-12 (10 ng/ml). The CD8<sup>+</sup> lymphocytes were restimulated on days 7 and 14 with autologous dendritic cells freshly infected with the ALVAC-MAGE-A1 and grown in complete Iscove's medium supplemented with IL-2 (10 U/ml) and IL-7 (5 ng/ml).

**[0155]** The microcultures containing proliferating CD8<sup>+</sup> T cells were assessed on day 21 for their capacity to lyse autologous EBV-B cells infected with vaccinia-MAGE-A1 (vP 1188). EBV-B cells infected with parental vaccinia (vP1170) were used as a negative control. Infected EBV-B cells (target cells) were washed and added to the responder cells at an effector to target ratio of approximately 40:1. Unlabeled K562 cells were also added ( $5 \times 10^4$  per V-bottomed microwell) to block natural killer activity. Chromium release was measured after incubation at 37°C for 4 hours. The individual microcultures were tested in duplicate on each target. In a first experiment, an anti-MAGE-A1 reactivity was detected in 3 microcultures out of 96. 13% of the microcultures contained responder cells that lysed targets infected with either vaccinia or vaccinia-MAGE-A1, but not the uninfected targets. This result indicated that the ALVAC and vaccinia vectors shared antigens recognized by CTL. In a second experiment, 2 microcultures scored positive in their anti-MAGE-A1 reactivity.

**[0156]** The positive microcultures (i.e., those that recognize autologous EBV-B cells infected with vaccinia-MAGE-A1 construct) were cloned by limiting dilution using, as stimulating cells, either autologous PHA-activated T cells transduced with a retrovirus encoding MAGE-A1, or autologous EBV-B cells transduced with the same retrovirus ( $5 \times 10^3$  to  $10^4$  cells per well in a 96-well plate). Allogeneic EBV-B cells ( $5 \times 10^3$  to  $10^4$  LG2-EBV-B cells per well in a 96-well plate) were used

as feeder cells. CTL clones were tested for specific lysis of autologous EBV-B cells infected with the vaccinia-MAGE-A1 construct. The established CTL clones were maintained in complete IMDM supplemented with IL-2 (50 U/ml) and 0.5 µg/ml purified PHA (instead of stimulator cells) and passaged by weekly restimulation with allogeneic EBV-B cells (1.5x10<sup>6</sup> LG2-EBV-B cells per well in a 24-well plate).

**[0157]** Clone LB1118 466/D3.31 was identified as a positive clone that recognized autologous EBV-B cells infected with vaccinia-MAGE-A1 (**Figure 7A**), or EBV-B transduced with a retrovirus encoding MAGE-A1.

#### Identification of the Peptide and the Presenting Molecule

**[0158]** To identify the HLA molecule that presents the MAGE-A1 peptide by CTL clone LB1118 466/D3.31, COS cells were transfected with the MAGE-A1 cDNA, together with cDNAs coding for one of the putative HLA presenting molecules. These transfected cells were then tested for their ability to stimulate the CTL clone to produce TNF. CTL clone LB1118 466/D3.31 produced TNF upon stimulation by COS cells transfected with MAGE-A1 and HLA-Cw2 (**Figure 7B**). To identify the MAGE-A1 peptide recognized by this CTL clone, a set of MAGE-A1 peptides of 12 amino acids that overlapped by 8 amino acids were screened. Autologous EBV-B cells were incubated with each of these peptides at a concentration of 1 µM, and tested for recognition by the CTL in a chromium release assay. Peptide ASAFPTTINFTR (MAGE-A1<sub>61-72</sub>) (SEQ ID NO: 45) scored positive whereas the 16 amino-acid peptide SPQGASAFPTTINFTR (MAGE-A1<sub>57-72</sub>) (SEQ ID NO: 46) scored negative. As information was not available for the residues anchoring a peptide in an HLA-Cw2 molecules, a number of shorter peptides were tested. Peptide SAFPTTINF (MAGE-A1<sub>62-70</sub>) (SEQ ID NO: 47) was subsequently found to be the shortest peptide capable of efficiently sensitizing autologous target cells to lysis by CTL clone LB1118 466/D3.31, with a half-maximal lysis obtained at ~0.1nM (**Figure 7C**). The natural processing of the antigen was shown by the lysis by CTL clone LB1118 466/D3.31 of HLA-Cw2 tumor cell lines that express MAGE-A1 (**Figure 7D**).

#### EXAMPLE 11

##### A MAGE-A1 PEPTIDE PRESENTED BY HLA-A28 TO CTL CLONE LB1801 456/H8.33

**[0159]** Dendritic cells were derived from donor LB 1801 (HLA-A\*0201, A28, B\*4401, B\*5301, Cw4, Cw\*0501). CTL clone LB1801 456/H8.33 was isolated by following essentially the same procedure as described in Example 10.

**[0160]** Briefly, immature dendritic cells derived from blood monocytes were infected with ALVAC-MAGE-A1 and used to stimulate autologous CD8<sup>+</sup>T cells in the presence of IL-6 and IL-12. Responder cells were restimulated once a week with autologous dendritic cells, infected with ALVAC-MAGE-A1, in the presence of IL-2 and IL-7. Responder cells were tested on day 28 for their lytic activity on autologous EBV-transformed B (EBV-B) cells infected with a vaccinia virus encoding MAGE-A1 (vaccinia-MAGE-A1).

**[0161]** Positive microcultures were subject to limiting dilution using EBV-B cells infected with *Yersinia*-MAGE-A1 as stimulating cells. CTL clone LB1801 456/H8.33 lysed autologous EBV-B cells infected with vaccinia-MAGE-A1 (**Figure 8A**). CTL clone LB1801 456/H8.33 produced TNF upon stimulation by COS-7 cells transfected with HLA-A28 and MAGE-A1 (**Figure 8B**). Peptide EYVDGREHSA (MAGE-A1<sub>222-231</sub>) (SEQ ID NO: 48) produced half-maximal lysis of target cells at 0.3 nM (**Figure 8C**). A tumor cell line expressing MAGE-A1 and HLA-A28 was lysed by the CTL, but the lysis was lower than that obtained with cells infected with vaccinia-MAGE-A1 (**Figure 8C**).

#### EXAMPLE 12

##### A MAGE-A3 PEPTIDE PRESENTED BY HLA-B40 TO CTLS

##### Processing of human blood

**[0162]** Blood samples from donor LB 1841 (HLA-A3, -B35, -B40, Cw3, -Cw4) were processed as described in Example 6, except that:

1. the interphase containing the PBMC was harvested and then washed 3 times (or more) in cold phosphate buffer solution with 2 mM EDTA in order to eliminate the remaining platelets;
2. monocyte-derived dendritic cells (DC) were frozen on day 6. On the day of stimulation, DC were thawed and infected with a recombinant adenovirus encoding MAGE-A3, at a multiplicity of infection (MOI) of 500.

##### Isolation of CTL clones specific for MAGE-A3

**[0163]** Dendritic cells obtained from the blood sample of donor LB 1841 were infected with ALVAC-MAGE-A3 and

cocultured with autologous CD8<sup>+</sup> cells following essentially the same procedure as described in Example 7.

**[0164]** After several rounds of stimulation, the microculture was tested for specific lysis of autologous target cells following essentially the same procedure as described in Example 7, except that the vaccinia samples were sonicated for 30 seconds prior to use for infection of EBV-B target cells.

**[0165]** Microculture 526/F7, identified as containing cells that specifically lysed autologous EBV-B cells infected with vaccinia-MAGE-A3, was cloned by limiting dilution using, as stimulating cells, autologous EBV-B cells infected with recombinant ALVAC-MAGE-A3 (vCP1563) at a multiplicity of infection of 30 (the ALVAC-MAGE-A3 sample was also sonicated 30 sec before use), or with PHA, according to the following scheme:

First week: stimulators = ALVAC-MAGE-A3 (vCP1563) infected EBV-B cells in complete IMDM medium supplemented with 50 U IL-2/ml, 2.5 ng IL-12/ml and 5 U IL-4/ml;  
 Second week: stimulators = ALVAC-MAGE-A3 (vCP1563) infected EBV-B cells in complete IMDM medium supplemented with 50 U IL-2/ml;  
 Third week: PHA (0.5 µg/ml) in complete IMDM medium supplemented with 50 U/ml of IL-2;  
 Fourth week: PHA (0.5 µg/ml) in complete IMDM medium supplemented with 50 U/ml of IL-2, 5ng/ml of IL-7 + gentamicin (15 µg/ml) + MRA 0.5 g/ml (from ICN);  
 Fifth and sixth week: stimulators = EBV-B cells infected with Yersinia-MAGE-A3(aa147-314) and EBV-B cells infected with Yersinia-MAGE-A3(aa1-199) in complete IMDM medium supplemented with 50 U/ml of IL-2, 2.5ng/ml of IL-12, 5 U/ml IL-4 + gentamicin (15 µg/ml);  
 Seventh week and each week thereafter: PHA (0.2 µg/ml) in complete IMDM medium supplemented with 50 U/ml of IL-2, 5 U/ml of IL-4 + gentamicin (15 µg/ml).

**[0166]** CTL clones were maintained in culture by weekly restimulation.

**[0167]** The clones were tested for specific lysis of autologous EBV-immortalized B cells infected with the vaccinia-MAGE-A3 construct, or with the parental vaccinia as a negative control. Clone LB1841 526/F7.1 was found positive (**Figure 9A**) and was used in the following experiments.

#### **The MAGE-A3 epitope is presented to CTL LB1841 526/F7.1 by HLA-B40.**

**[0168]** To identify the HLA molecule that presents the MAGE-A3 epitope recognized by CTL clone LB1841 526/F7.1, COS cells were transfected with the MAGE-A3 cDNA together with cDNAs coding for each of the putative HLA presenting molecules. In brief, 1.5 x 10<sup>4</sup> COS cells distributed in microwells were cotransfected with 50 ng of plasmid pcDNA3-MAGE-A3, 50 ng of plasmid containing coding sequences for HLA molecules and 1 µl of Lipofectamine (Gibco BRL). The HLA coding sequences were isolated from various individuals; in particular, the HLA-B40 cDNA was obtained by RT-PCR using RNA from tumor cell line HA-7-RCC as a template. This PCR product cDNA was inserted in pcDNA3 (Invitrogen). The COS cells were incubated 24 hours at 37°C and 8% CO<sub>2</sub>. These transfectants were then tested for their ability to stimulate the production of TNF by clone LB1841 526/F7.1. Briefly, 2500 CTLs were added to the microwells containing the transfectants, in a total volume of 100 µl of Iscove's complete medium containing 25 U/ml of IL-2. After 24 hours, the supernatant was collected and the TNF content was determined by testing the cytotoxic effect of the supernatant on cells of WEHI-164 clone 13 in a standard MTT colorimetric assay. The cells transfected with both HLA-B40 and MAGE-A3 stimulated CTL clone LB1841 526/F7.1 to produce TNF (**Figure 9B**). Cos cells transfected with MAGE-A3 or HLA-B40 alone did not stimulate the CTL clone.

#### **Identification of the antigenic peptide**

**[0169]** To identify the MAGE-A3 peptide recognized by CTL clone LB1841 526/F7.1, a set of peptides of 16 amino acids that overlapped by 12 amino acids and covered the entire MAGE-A3 protein sequence, was screened. Autologous EBV-B cells were incubated with each of these peptides at a concentration of 1 µg/ml, and tested for recognition by CTL clone LB1841 526/F7.1 in a chromium release assay at an effector to target cell ratio of 5:1. Peptide AALSRKVAELVH-FLL (SEQ ID NO: 54) scored positive. The sequence of this peptide was screened for prediction of an HLA-B40 binding peptide with the software available at "[http://bimas.dcrt.nih.gov/molbio/hla\\_bind/index.html](http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html)". Peptide AELVHFLLL (MAGE-A3 114-122) (SEQ ID NO: 55) had the highest score. It was tested in a cytotoxicity assay with CTL clone LB1841 526/F7.1 and produced half-maximal lysis of autologous EBV-B target cells at ~7nM (**Figure 9C**).

#### **Recognition by CTL clone LB1841 526/F7.1 of HLA-B40 cells expressing MAGE-A3**

**[0170]** CTL clone LB1841 526/F7.1 was also able to lyse melanoma cell lines that expresses MAGE-A3 which were obtained from HLA-B40 positive patients, e.g., LB-43-MEL (**Figure 9D**). Some melanoma cells, e.g., SK-MEL-28 and



SK-31-MEL, were not lysed by clone LB1841 526/F7.1, even though the level of expression of MAGE-A3 appeared to be appropriate in these cells. The peptide-pulsed cells were also insensitive to the CTL lysis. The lack of lysis was likely due to downregulation of the HLA expression in these melanoma cells, since treatment of SK-MEL-28 cells with IFN- $\gamma$  increased the lysis of these cells by clone LB1841 526/F7.1 (IFN- $\gamma$  is known to upregulate HLA expression in certain cells).

### EXAMPLE 13

#### A MAGE-A1 PEPTIDE PRESENTED BY HLA-B7 MOLECULES TO CYTOLYTIC T LYMPHOCYTES

##### Processing of human blood

[0171] Blood samples from donor LB 1803 (HLA-A2, -A32, B7, -B60) were processed as described in Example 12.

##### Isolation of CTL clones specific for MAGE-A1

[0172] Dendritic cells obtained from the blood sample of donor LB 1803 were infected with ALVAC-MAGE-A1 and cocultured with autologous CD8<sup>+</sup> cells following essentially the same procedure as described in Example 7 except that 15  $\mu$ g/ml gentamycin was added to the culture medium.

[0173] After several rounds of stimulation, the microculture was tested for specific lysis of autologous target cells following essentially the same procedure as described in Example 7, except that the vaccinia samples were sonicated for 30 seconds prior to use for infection of EBV-B target cells.

[0174] Microculture 483/G8, identified as containing cells that specifically lysed autologous EBV-B cells infected with recombinant vaccinia (WR-MAGE-A1), was cloned by limiting dilution using, for the first two weekly stimulations, irradiated autologous EBV-B cells infected with Yersinia-MAGE-A1 as stimulating cells, irradiated LG2-EBV as feeder cells, IL-2 (50 U/ml) and gentamycin (15  $\mu$ g/ml). CTL clones were then maintained in culture by weekly restimulation with PHA (0.5  $\mu$ g/ml), feeder cells and IL-2.

[0175] The clones were tested for specific lysis of autologous EBV-immortalized B cells infected with recombinant vaccinia (WR-MAGE-A1), or with the parental vaccinia as a negative control. Clone LB1803 483/G8.4 was found positive (Figure 10A) and was used in the following experiments.

##### The MAGE-A1 epitope is presented to CTL by HLA-B7 molecules.

[0176] Donor LB 1803 was typed HLA-A2, -A32, -B7, -B60. To identify the HLA molecule that presents the MAGE-A1 epitope recognized by CTL clone LB1803 483/G8.4, COS-7 cells were transfected with the MAGE-A1 cDNA together with cDNAs coding for the putative HLA presenting molecules. In brief, 1.5 x 10<sup>4</sup> COS-7 cells distributed in microwells were cotransfected with 50 ng of plasmid pcDNA3-MAGE-A1, 50 ng of plasmid containing coding sequences for HLA molecules and 1  $\mu$ l of Lipofectamine (Gibco BRL). The HLA coding sequences were isolated from various individuals; in particular, the HLA-B7 cDNA was obtained by RT-PCR using RNA from tumor cell line LB23-SAR as a template. This PCR product was inserted in pcDSRalpha. The transfected COS-7 cells were incubated 24 hours at 37°C and 8% CO<sub>2</sub>. These transfectants were then tested for their ability to stimulate the production of TNF by clone LB1803 483/G8.4. Briefly, 2000 CTL were added to the microwells containing the transfectants, in a total volume of 100  $\mu$ l of Iscove's complete medium containing 25 U/ml of IL-2. After 24 hours, the supernatant was collected and the TNF content was determined by testing the cytotoxic effect of the supernatant on cells of WEHI-164 clone 13 in a standard MTT colorimetric assay. The cells transfected with both HLA-B7 and MAGE-A1 stimulated CTL clone LB1803 483/G8.4 to produce TNF (Figure 10B). COS-7 cells transfected with HLA-B7 and either MAGE-A2, -A3, -A4, -A6, -A8, -A9, -A10, -A11, -A12, -B1, -B2, or -C2 were unable to stimulate CTL clone LB1803 483/G8.4 to produce TNF.

##### Identification of the antigenic peptide

[0177] To identify the MAGE-A1 peptide recognized by CTL clone LB1803 483/G8.4, a set of peptides of 12 amino acids, that overlapped by 8 amino acids and covered the entire MAGE-A1 protein sequence, was screened. Autologous EBV-B cells were incubated with each of these peptides at a concentration of 2  $\mu$ g/ml, and tested for recognition by CTL clone LB1803 483/G8.4 in a chromium release assay at an effector to target cell ratio of 20:1. Peptide RVRFFFPSLREA (MAGE-A1 289-300) (SEQ ID NO: 56) scored positive. The sequence of this peptide was screened for an HLA-B7 binding peptide with the software available at "[http://bimas.dcrt.nih.gov/molbio/hla\\_bind/index.html](http://bimas.dcrt.nih.gov/molbio/hla_bind/index.html)". Peptide RVRFFFPSL (MAGE-A1 289-297) (SEQ ID NO: 57) had the highest score. It was tested in a cytotoxicity assay with CTL clone LB1803 483/G8.4 (E/T ratio of 20:1) and produced half-maximal lysis of autologous EBV-B target cells at ~20nM (Figure 10D).

**Recognition by CTL clone LB1803 483/G8.4 of HLA-B7 cells expressing MAGE-A1.**

**[0178]** CTL clone LB1803 483/G8.4 was also able to lyse HLA-B7 melanoma cell line ME275 clone 2 that expressed MAGE-A1 (**Figure 10D**). Melanoma cell line ME190DA was also lysed but only after treatment for 72h with 100 U/ml of IFN-gamma.

**Claims**

1. An isolated CTL clone specific for a peptide/HLA complex, wherein said complex is selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVFHLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.
2. An isolated antigenic peptide, wherein said peptide is selected from the group consisting of DPARYEFLW (SEQ ID NO: 42), GVDGREHTV (SEQ ID NO: 44), SAFPTTINF (SEQ ID NO: 47), and AELVFHLLL (SEQ ID NO: 55).
3. An isolated nucleic acid molecule encoding said peptide of claim 2.
4. An isolated peptide/HLA complex, wherein said complex is selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVFHLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.
5. An antigen presenting cell expressing said peptide/HLA complex of claim 4.
6. A pharmaceutical composition comprising a pharmaceutical carrier and at least one isolated CTL clone selected from the group consisting of a CTL clone specific for SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, a CTL clone specific for DPARYEFLW (SEQ ID NO: 42)/HLA-B53, a CTL clone specific for GVDGREHTV (SEQ ID NO: 44)/HLA-A2, a CTL clone specific for SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, a CTL clone specific for EVDGREHSA (SEQ ID NO: 48)/HLA-A28, a CTL clone specific for AELVFHLLL (SEQ ID NO: 55)/HLA-B40, and a CTL clone specific for RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.
7. A pharmaceutical composition comprising a pharmaceutical carrier and at least one peptide selected from the group consisting of DPARYEFLW (SEQ ID NO: 42), GVDGREHTV (SEQ ID NO: 44), SAFPTTINF (SEQ ID NO: 47), and AELVFHLLL (SEQ ID NO: 55).
8. A pharmaceutical composition comprising a pharmaceutical carrier and at least one isolated peptide/HLA complex selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVFHLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.
9. A pharmaceutical composition comprising a pharmaceutical carrier and at least one antigen presenting cell selected from the group consisting of an antigen presenting cell expressing SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, an antigen presenting cell expressing DPARYEFLW (SEQ ID NO: 42)/HLA-B53, an antigen presenting cell expressing GVDGREHTV (SEQ ID NO: 44)/HLA-A2, an antigen presenting cell expressing SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, an antigen presenting cell expressing EVDGREHSA (SEQ ID NO: 48)/HLA-A28, an antigen presenting cell expressing AELVFHLLL (SEQ ID NO: 55)/HLA-B40, and an antigen presenting cell expressing RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.
10. A method of detecting in a sample from a subject, the presence of a cell which abnormally expresses a peptide/HLA complex at the cell surface, wherein said peptide/HLA complex is any one of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVFHLLL (SEQ ID NO: 55)/HLA-B40, or RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, said method comprising contacting said sample with a CTL clone specific for said complex.
11. Use of peptide/HLA complex selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVFHLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.

YEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 for the preparation of an agent for in vitro diagnosing a pathological condition **characterized by** an abnormal expression of said peptide/HLA complex by detecting the presence of cells which abnormally express said peptide/HLA complex at the cell surface and wherein said pathological condition is cancer.

12. A method of detecting in a sample of a subject, the presence of CTL cells specific for a peptide/HLA complex, wherein said complex is selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, said method comprising contacting said sample with a cell which presents said peptide/HLA complex on the surface of said cell, and detecting a CTL response as an indication of the presence of said CTL cells.

13. Use of a peptide/HLA complex selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 for the preparation of an agent for in vitro diagnosing a pathological condition **characterized by** an abnormal expression of said peptide/HLA complex by detecting an increased frequency of CTL cells specific for said complex and wherein said pathological condition is cancer.

14. Use of a therapeutically effective amount of CTL cells specific for a complex selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 for the preparation of a medicament for treating a subject having a pathological condition **characterized by** abnormal expression of said peptide/HLA complex and wherein said pathological condition is cancer.

15. Use of a therapeutically effective amount of the peptide selected from the group consisting of DPARYEFLW (SEQ ID NO: 42), GVDGREHTV (SEQ ID NO: 44), SAFPTTINF (SEQ ID NO: 47), AELVHFLLL (SEQ ID NO: 55), and RVRFFFPSL (SEQ ID NO: 57) for the preparation of a medication for treating a subject having cancer, wherein said subject is **characterized by** abnormal expression of a peptide/HLA complex selected from the group of DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, AELVHFLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.

16. Use of a therapeutically effective amount of cells which present a complex on the cell surface wherein said complex is selected from the group consisting of SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40, and RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 for the preparation of a medication for treating a subject having a pathological condition **characterized by** abnormal expression of said peptide/HLA complex and wherein said pathological condition is cancer.

17. The use of claim 16, wherein said cells are autologous antigen presenting cells and wherein the presentation of said peptide/HLA complex on the cell surface is achieved by loading said cells with the peptide in said peptide/HLA complex.

18. The use of claim 16, wherein said cells are autologous antigen presenting cells and wherein the presentation of said peptide/HLA complex on the cell surface is achieved by transfecting said cells with a nucleotide sequence coding for the peptide in said peptide/HLA complex.

## Patentansprüche

1. Isolierter CTL-Klon, der für einen Peptid/HLA-Komplex spezifisch ist, wobei dieser Komplex ausgewählt ist aus der Gruppe bestehend aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.

2. Isoliertes antigenes Peptid, wobei das Peptid ausgewählt ist aus DPARYEFLW (SEQ ID NO: 42), GVDGREHTV

(SEQ ID NO: 44), SAFPTTINF (SEQ ID NO: 47) und AELVHFLLL (SEQ ID NO: 55).

3. Isoliertes Nukleinsäuremolekül, codierend das Peptid gemäss Anspruch 2.

4. Isolierter Peptid/HLA-Komplex, wobei dieser Komplex ausgewählt ist aus der Gruppe bestehend aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDYDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.

5. Antigen-präsentierende Zelle, die den Peptid/HLA-Komplex gemäss Anspruch 4 exprimiert.

6. Pharmazeutische Zusammensetzung, umfassend einen pharmazeutischen Träger und mindestens einen isolierten CTL-Klon, der aus der Gruppe ausgewählt ist, die aus einem CTL-Klon besteht, der für SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3 spezifisch ist, einem CTL-Klon, der für DPARYEFLW (SEQ ID NO: 42)/HLA-B53 spezifisch ist, einem CTL-Klon, der für GVDYDGREHTV (SEQ ID NO: 44)/HLA-A2 spezifisch ist, einem CTL-Klon, der für SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2 spezifisch ist, einem CTL-Klon, der für EVYDGREHSA (SEQ ID NO: 48)/HLA-A28 spezifisch ist, einem CTL-Klon, der für AELVHFLLL (SEQ ID NO: 55)/HLA-B40 spezifisch ist, und einem CTL-Klon, der für und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 spezifisch ist.

7. Pharmazeutische Zusammensetzung, umfassend einen pharmazeutischen Träger und mindestens ein Peptid, ausgewählt aus der Gruppe bestehend aus DPARYEFLW (SEQ ID NO: 42), GVDYDGREHTV (SEQ ID NO: 44), SAFPTTINF (SEQ ID NO: 47) und AELVHFLLL (SEQ ID NO: 55).

8. Pharmazeutische Zusammensetzung, umfassend einen pharmazeutischen Träger und mindestens einen isolierten Peptid/HLA-Komplex, ausgewählt aus der Gruppe bestehend aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDYDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.

9. Pharmazeutische Zusammensetzung, umfassend einen pharmazeutischen Träger und mindestens eine Antigen-präsentierende Zelle, ausgewählt aus der Gruppe, die aus einer Antigen-präsentierenden Zelle besteht, die SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3 exprimiert, einer Antigen-präsentierenden Zelle, die DPARYEFLW (SEQ ID NO: 42)/HLA-B53 exprimiert, einer Antigen-präsentierenden Zelle, die GVDYDGREHTV (SEQ ID NO: 44)/HLA-A2 exprimiert, einer Antigen-präsentierenden Zelle, die SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2 exprimiert, einer Antigen-präsentierenden Zelle, die EVYDGREHSA (SEQ ID NO: 48)/HLA-A28 exprimiert, einer Antigen-präsentierenden Zelle, die AELVHFLLL (SEQ ID NO: 55)/HLA-B40 exprimiert und einer Antigen-präsentierenden Zelle besteht, die RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 exprimiert.

10. Verfahren zum Nachweisen des Vorhandenseins einer Zelle, die einen Peptid/HLA-Komplex abnormal an der Zelloberfläche exprimiert, in einer Probe eines Individuums, wobei dieser Peptid/HLA-Komplex irgendeiner aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDYDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 oder RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 ist, wobei das Verfahren das In-Kontakt-Bringen dieser Probe mit einem CTL-Klon umfasst, der für diesen Komplex spezifisch ist.

11. Verwendung eines Peptid/HLA-Komplexes, ausgewählt aus der Gruppe bestehend aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDYDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, zur Herstellung eines Mittels zur in vitro-Diagnostik eines pathologischen Zustands, der durch eine abnormale Expression dieses Peptid/HLA-Komplexes charakterisiert ist, durch Nachweisen des Vorhandenseins von Zellen, die den Peptid/HLA-Komplex an der Zelloberfläche abnormal exprimieren und wobei der pathologische Zustand Krebs ist.

12. Verfahren zum Nachweisen des Vorhandenseins von CTL-Zellen, die für einen Peptid/HLA-Komplex spezifisch sind, in einer Probe eines Individuums, wobei dieser Komplex ausgewählt ist aus der Gruppe bestehend aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDYDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, wobei das Verfahren das In-Kontakt-Bringen

dieser Probe mit einer Zelle umfasst, die diesen Peptid/HLA-Komplex an der Oberfläche dieser Zelle exprimiert, und Nachweisen einer CTL-Antwort als Hinweis auf das Vorhandensein dieser CTL-Zellen.

13. Verwendung eines Peptid/HLA-Komplexes, ausgewählt aus der Gruppe bestehend aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, zur Herstellung eines Mittels zur in vitro-Diagnostik eines pathologischen Zustands, der durch eine abnormale Expression dieses Peptid/HLA-Komplexes charakterisiert ist, durch Nachweisen einer erhöhten Häufigkeit von CTL-Zellen, die für diesen Komplex spezifisch sind und wobei dieser pathologische Zustand Krebs ist.
14. Verwendung einer therapeutisch wirksamen Menge an CTL-Zellen, die für einen Komplex spezifisch sind, der aus der Gruppe ausgewählt ist, die aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7 besteht, zur Herstellung eines Medikaments zur Behandlung eines Individuums mit einem pathologischen Zustand, der durch eine abnormale Expression dieses Peptid/HLA-Komplexes charakterisiert ist und wobei dieser pathologische Zustand Krebs ist.
15. Verwendung einer therapeutisch wirksamen Menge des Peptids, das aus der Gruppe ausgewählt ist die aus DPARYEFLW (SEQ ID NO: 42), GVDGREHTV (SEQ ID NO: 44), SAFPTTINF (SEQ ID NO: 47), AELVHFLLL (SEQ ID NO: 55) und RVRFFFPSL (SEQ ID NO: 57) besteht, zur Herstellung eines Medikaments zur Behandlung eines Individuums mit Krebs, wobei dieses Individuum durch abnormale Expression eines Peptid/HLA-Komplexes charakterisiert ist, ausgewählt aus der Gruppe bestehend aus DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7.
16. Verwendung einer therapeutisch wirksamen Menge an Zellen, die einen Komplex an der Zelloberfläche präsentieren, wobei dieser Komplex ausgewählt ist aus der Gruppe bestehend aus SAYGEPRKL (SEQ ID NO: 2)/HLA-Cw3, DPARYEFLW (SEQ ID NO: 42)/HLA-B53, GVDGREHTV (SEQ ID NO: 44)/HLA-A2, SAFPTTINF (SEQ ID NO: 47)/HLA-Cw2, EVYDGREHSA (SEQ ID NO: 48)/HLA-A28, AELVHFLLL (SEQ ID NO: 55)/HLA-B40 und RVRFFFPSL (SEQ ID NO: 57)/HLA-B7, zur Herstellung eines Medikaments zur Behandlung eines Individuums mit einem pathologischen Zustand, der durch eine abnormale Expression dieses Peptid/HLA-Komplexes charakterisiert ist, und wobei dieser pathologische Zustand Krebs ist.
17. Verwendung gemäß Anspruch 16, wobei diese Zellen autologe Antigen-präsentierende Zellen sind und wobei die Präsentation dieses Peptid/HLA-Komplexes auf der Zelloberfläche durch Beladen dieser Zellen mit dem Peptid in diesem Peptid/HLA-Komplex erreicht wird.
18. Verwendung gemäß Anspruch 16, wobei diese Zellen autologe Antigen-präsentierende Zellen sind und wobei die Präsentation dieses Peptid/HLA-Komplexes auf der Zelloberfläche durch Transfizieren dieser Zellen mit einer Nukleotidsequenz erzielt wird, die für das Peptid in diesem Peptid/HLA-Komplex codiert.

## Revendications

1. Clone de CTL isolé spécifique d'un complexe de peptide/HLA, ledit complexe étant choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLA-Cw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDGREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7.
2. Peptide antigénique isolé, ledit peptide étant choisi dans le groupe comprenant DPARYEFLW (SEQ ID N° : 42), GVDGREHTV (SEQ ID N° : 44), SAFPTTINF (SEQ ID N° : 47) et AELVHFLLL (SEQ ID N° : 55).
3. Molécule d'acide nucléique isolée codant pour ledit peptide selon la revendication 2.
4. Complexe de peptide/HLA isolé, ledit complexe étant choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLA-Cw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDGREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF

(SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7.

5. Cellule de présentation de l'antigène, exprimant ledit complexe de peptide/HLA selon la revendication 4.

6. Composition pharmaceutique comprenant un véhicule pharmaceutique et au moins un clone de CTL isolé choisi dans le groupe comprenant un clone de CTL spécifique de SAYGEPRKL (SEQ ID N° : 2) / HLACw3, un clone de CTL spécifique de DPARYEFLW (SEQ ID N° : 42) / HLA-B53, un clone de CTL spécifique de GVDYDREHTV (SEQ ID N° : 44) / HLA-A2, un clone de CTL spécifique de SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, un clone de CTL spécifique de EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, un clone de CTL spécifique de AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et un clone de CTL spécifique de RVRFFFPSL (SEQ ID N° : 57) / HLA-B7.

7. Composition pharmaceutique comprenant un véhicule pharmaceutique et au moins un peptide choisi dans le groupe comprenant DPARYEFLW (SEQ ID N° : 42), GVDYDREHTV (SEQ ID N° : 44), SAFPTTINF (SEQ ID N° : 47) et AELVHFLLL (SEQ ID N° : 55).

8. Composition pharmaceutique comprenant un véhicule pharmaceutique et au moins un complexe de peptide/HLA isolé choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLACw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDYDREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7.

9. Composition pharmaceutique comprenant un véhicule pharmaceutique et au moins une cellule de présentation de l'antigène choisie dans le groupe comprenant une cellule de présentation de l'antigène exprimant SAYGEPRKL (SEQ ID N° : 2) / HLACw3, une cellule de présentation de l'antigène exprimant DPARYEFLW (SEQ ID N° : 42) / HLA-B53, une cellule de présentation de l'antigène exprimant GVDYDREHTV (SEQ ID N° : 44) / HLA-A2, une cellule de présentation de l'antigène exprimant SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, une cellule de présentation de l'antigène exprimant EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, une cellule de présentation de l'antigène exprimant AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et une cellule de présentation de l'antigène exprimant RVRFFFPSL (SEQ ID N° : 57) / HLA-B7.

10. Procédé de détection dans un échantillon d'un sujet, de la présence d'une cellule qui exprime de façon anormale un complexe de peptide/HLA à la surface cellulaire, ledit complexe de peptide/HLA étant l'un quelconque des complexes SAYGEPRKL (SEQ ID N° : 2) / HLACw3, DPARYEFLW - (SEQ ID N° : 42) / HLA-B53, GVDYDREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7, ledit procédé comprenant la mise en contact dudit échantillon avec un clone de CTL spécifique dudit complexe.

11. Utilisation d'un complexe de peptide/HLA choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLACw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDYDREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7, pour la préparation d'un agent pour le diagnostic *in vitro* d'un état pathologique **caractérisé par** une expression anormale dudit complexe de peptide/HLA en détectant la présence des cellules qui expriment de façon anormale, ledit complexe de peptide/HLA à la surface cellulaire et ledit état pathologique étant le cancer.

12. Procédé de détection dans un échantillon d'un sujet, de la présence de cellules de CTL spécifiques d'un complexe de peptide/HLA, ledit complexe étant choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLACw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDYDREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7, ledit procédé comprenant la mise en contact dudit échantillon avec une cellule qui présente ledit complexe de peptide/HLA sur la surface de ladite cellule et la détection d'une réponse des CTL à titre d'indication de la présence desdites cellules de CTL.

13. Utilisation d'un complexe de peptide/HLA choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLACw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDYDREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7, pour la préparation d'un agent pour le diagnostic *in vitro* d'un état pathologique **caractérisé par** une expression anormale dudit complexe de peptide/HLA en détectant une augmentation de la fréquence de cellules de CTL spécifiques dudit complexe, et ledit état pathologique étant le cancer.

14. Utilisation d'une quantité thérapeutiquement efficace de cellules de CTL spécifiques d'un complexe choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLA-Cw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDYD-GREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7 pour la préparation d'un médicament pour traiter un sujet présentant un état pathologique, **caractérisé par** l'expression anormale dudit complexe de peptide/HLA, ledit état pathologique étant le cancer.
15. Utilisation d'une quantité thérapeutiquement efficace du peptide choisi dans le groupe comprenant DPARYEFLW (SEQ ID N° : 42), GVDYDGREHTV (SEQ ID N° : 44), SAFPTTINF (SEQ ID N° : 47), AELVHFLLL (SEQ ID N° : 55) et RVRFFFPSL (SEQ ID N° : 57), pour la préparation d'un médicament pour traiter un sujet souffrant d'un cancer, ledit sujet étant **caractérisé par** l'expression anormale d'un complexe de peptide/HLA choisi dans le groupe comprenant DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDYDGREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7.
16. Utilisation d'une quantité thérapeutiquement efficace de cellules qui présentent un complexe sur la surface cellulaire, ledit complexe étant choisi dans le groupe comprenant SAYGEPRKL (SEQ ID N° : 2) / HLA-Cw3, DPARYEFLW (SEQ ID N° : 42) / HLA-B53, GVDYDGREHTV (SEQ ID N° : 44) / HLA-A2, SAFPTTINF (SEQ ID N° : 47) / HLA-Cw2, EVYDGREHSA (SEQ ID N° : 48) / HLA-A28, AELVHFLLL (SEQ ID N° : 55) / HLA-B40 et RVRFFFPSL (SEQ ID N° : 57) / HLA-B7, pour la préparation d'un médicament pour traiter un sujet ayant un état pathologique **caractérisé par** l'expression anormale dudit complexe de peptide/HLA et ledit état pathologique étant le cancer.
17. Utilisation selon la revendication 16, dans laquelle lesdites cellules sont des cellules de présentation de l'antigène autologues et la présentation dudit complexe de peptide/HLA sur la surface cellulaire étant obtenue en chargeant lesdites cellules avec le peptide dans ledit complexe de peptide/HLA.
18. Utilisation selon la revendication 16, dans laquelle lesdites cellules sont des cellules de présentation de l'antigène autologues et la présentation dudit complexe de peptide/HLA sur la surface cellulaire étant obtenue par transfection desdites cellules avec une séquence de nucléotides codant pour le peptide dans ledit complexe de peptide/HLA.






FIG. 2A





FIG. 2B



A MAGE-1 antigenic peptide is presented by HLA-Cw3 to CTL clone F3/2

FIGURE 3A




FIGURE 3B





FIGURE 3C




FIGURE 3D

1998-PvB-22 (M1Cw3) CTL

A MAGE-1 antigenic peptide is presented by HLA-B53 to CTL clone 456/H7.11

FIGURE 4B




FIGURE 4A




FIGURE 4C

No tumor cell line available  
MAGE-1 +  
HLA-B53 +

FIGURE 4

1998-PvdB-18 (M1053 CTL)

Figure 5

A MAGE-4 antigenic peptide is presented by HLA-A2 to CTL clone H4/13




FIGURE 5A




FIGURE 5B




FIGURE 5C




FIGURE 5D  
1998-PvDB 21 (MAGE CTL)

## FIG. 6



FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D






FIG.9A




FIG.9B




FIG.9C




FIG.9D




FIG.10A




FIG.10B




FIG.10C





FIG.10D



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- WO 9726328 A [0005]
- WO 9521630 A [0005]
- US 5342774 A [0029] [0109] [0137]
- US 4769330 A [0050]
- US 5756106 A [0051]
- US 5462871 A [0058]
- US 5558995 A [0058] [0072]
- US 5554724 A [0058]
- US 5585461 A [0058]
- US 5591430 A [0058]
- US 5554506 A [0058]
- US 5487974 A [0058]
- US 5530096 A [0058]
- US 5519117 A [0058]
- FR 9603207 [0119]

## Non-patent literature cited in the description

- **Male et al.** Advanced Immunology. J.P. Lipincott Company, 1987 [0002]
- **Van den Eynde ; van der Bruggen.** *Curr. Opin. Immunol.*, 1997, vol. 9, 684-693 [0003] [0056]
- **Sahin et al.** *Curr. Opin. Immunol.*, 1997, vol. 9, 709-716 [0003] [0056]
- **Shawler et al.** Advances in Pharmacology. Academic Press, Inc, 1997, vol. 40, 309-337 [0003]
- **van der Bruggen et al.** *Science*, 1991, vol. 254, 1643-1647 [0004]
- **Boon et al.** *Cancer Surveys*, 1992, vol. 13, 23-37 [0004]
- **T. Boon.** *Int. J. Cancer*, 1993, vol. 54, 177-180 [0004]
- **T. Boon.** *Advances Cancer Res.*, 1992, vol. 58, 177-209 [0004]
- **Toso J. F. et al.** *Cancer Research*, vol. 56, 16-20 [0005]
- **Mcelrath M. J. et al.** *Aids Research and Human Retroviruses*, 1994, vol. 10, S69-S72 [0005]
- **Hammond S. A. et al.** *Journal of Immunological Methods*, vol. 213, 73-85 [0005]
- **Riddell S. R. et al.** *Journal of Immunology*, vol. 146, 2795-2804 [0005]
- **Knuth et al.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 2804-2808 [0029]
- **Van Den Eynde et al.** *Int. J. Cancer*, 1989, vol. 44, 634-640 [0029]
- **Coligan et al.** *Current Protocols in Immunology*, 1994 [0034]
- Cross talk between Yersinia and eukaryotic cells, Society for General Microbiology Symposium. **Cornelis.** Molecular aspects of host-pathogen interactions. Cambridge University Press, 1997, vol. 55 [0046]
- **Starnbach et al.** *J. Immunol.*, 1994, vol. 153, 1603 [0046]
- **Rosqvist et al.** *EMBD J.*, 1994, vol. 13, 964 [0047]
- **W. Herr et al.** *J. Immunol. Methods*, 1997, vol. 203, 141-152 [0047]
- **W. Herr et al.** *J. Immunol. Methods*, 1996, vol. 191, 131-142 [0047]
- **Panicali et al.** *J. Virol.*, 1981, vol. 37, 1000-1010 [0050]
- **Perkins et al.** *J. Virol.*, 1989, vol. 63, 3829-3936 [0050] [0112]
- **Cox et al.** *Virology*, 1993, vol. 195, 845-850 [0051]
- **Tartaglia et al.** *J. Virology*, 1993, vol. 67, 2370-2375 [0051]
- **Taylor et al.** *Virology*, 1992, vol. 187, 321-328 [0051]
- **Thompson et al.** *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 5845-5849 [0054]
- **F. et al.** *J. Virol.*, 1997, vol. 71, 2715-2721 [0057]
- **An et al.** *J. Virol.*, 1997, vol. 71, 2292-2302 [0057]
- **Bruna-Romero et al.** *Hepatology*, 1997, vol. 25, 470-477 [0057]
- **Achour et al.** *J. Virol.*, 1996, vol. 70, 6741-6750 [0057]
- **Allsopp et al.** *Eur. J. Immunol.*, 1996, vol. 26, 1951-1958 [0057]
- **Nomura et al.** *J. Immunol. Methods*, 1996, vol. 193, 4149 [0057]
- **An et al.** *Infect. Immun.*, 1996, vol. 64, 1685-1693 [0057]
- **Gao et al.** *J. Immunol.*, 1995, vol. 155, 5519-5526 [0057]
- **Bauer et al.** *Scand. J. Immunol.*, 1995, vol. 42, 317-323 [0057]
- **Hsu et al.** *Immunology*, 1995, vol. 85, 347-350 [0057]
- **Salvucci et al.** *J. Gen. Virol.*, 1995, vol. 69, 1122-1131 [0057]
- **Franco et al.** *J. Gen. Virol.*, 1993, vol. 74, 2579-2586 [0057]
- **Gilbert et al.** *Nature Biotech.*, 1997, vol. 15, 1280-1283 [0057]

- **Garboczi et al.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 3429-3433 [0077]
- **Altman et al.** *Science*, 1996, vol. 274, 94-96 [0077] [0095]
- **Greenberg.** *J. Immunol.*, 1986, vol. 136 (5), 1917 [0091]
- **Riddel et al.** *Science*, 1992, vol. 257, 238 [0091]
- **Lynch et al.** *Eur. J. Immunol.*, 1991, vol. 21, 1403 [0091]
- **Kast.** *Cell*, 1989, vol. 59, 603 [0091]
- **Nestle et al.** *Nature Medicine*, 1998, vol. 4, 328-332 [0093]
- **Thomson et al.** *PNAS*, 1995, vol. 92, 5845 [0095]
- **Dunbar et al.** *Current Biology*, 1998, vol. 8, 413-416 [0095]
- **Greenberg et al.** *J. Immunol.*, 1986, vol. 136, 1917 [0095]
- **Kast et al.** *Cell*, 1989, vol. 59, 603-614 [0095]
- **Sory et al.** *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 11998-12002 [0098]
- **K. Kaniga et al.** A wide-host range suicide vector for improving reverse genetics in gram-negative bacteria: inactivation of the blaA gene of *Yersinia enterocolitica*. *Gene*, 1991, vol. 109, 137-141 [0099]
- **M.R. Sarker et al.** An improved version of suicide vector pKNG101 for gene replacement in Gram-negative bacteria. *Mol. Microbiol.*, 1997, vol. 23, 409-411 [0099]
- **P. Wattiau et al.** SycE, a chaperone-like protein of *Yersinia enterocolitica* involved in the secretion of YopE. *Mol. Microbiol.*, 1993, vol. 8, 123-131 [0099]
- **S.D. Mills et al.** *Yersinia enterocolitica* induces apoptosis in macrophages by a process requiring functional type III secretion and translocation mechanisms and involving YopP, presumably acting as an effector protein. *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 12638-12643 [0099]
- **K. Kaniga et al.** *Gene*, 1991, vol. 109, 137-141 [0099]
- **M.R. Sarker ; G.R. Cornelis.** *Mol. Microbiol.*, 1997, vol. 23, 409-411 [0099]
- **S.D. Mills et al.** *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 12638-12643 [0099]
- **P. Wattiau ; G.R. Cornelis.** *Mol. Microbiol.*, 1993, vol. 8, 123-131 [0099]
- **Sory et al.** *Molecular Microbiology*, 1994, vol. 14, 583-594 [0101]
- **Sory et al.** *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 11998-12002 [0102]
- **Chakrabati et al.** *Mol. Cell Biol.*, 1985, vol. 5, 34-33409 [0111]
- **Ausubel et al.** *Current Protocols in Molecular Cloning*. John Wiley & Sons [0114]
- **Ferrari et al.** *Blood*, 1997, vol. 90, 2406-2416 [0114]
- **Stratford-Perricaudet et al.** *J. Clin. Invest.*, 1992, vol. 90, 626-630 [0119]
- **Mavilio F. et al.** *Blood*, 1994, vol. 83, 1988-1997 [0121]
- **Mason ; Pasham.** *Tissue Antigens*, 1998, vol. 51, 417-466 [0143]